Tag: Metastasis

  • Progressive plasticity during colorectal cancer metastasis

    Progressive plasticity during colorectal cancer metastasis

    [ad_1]

    Patient biospecimen procurement and processing

    Tissue collection

    Patients undergoing synchronous colorectal resection and metastasectomy at MSKCC were identified by chart review, and those who had signed pre-procedure informed consent to MSK IRB protocols 06-107, 12-245, 14-244 and 22-404 for biospecimen collection were selected for this study. No statistical method was used to pre-determine sample size. Freshly resected surgical tissue in surplus of clinical diagnostic requirements was processed into single-cell suspensions for scRNA-seq analysis and, where sufficient tissue was available, processed to generate organoids. Portions were also fixed in formalin and embedded in paraffin. Tissue was generally processed within 1 h of surgical resection. Archival formalin-fixed, paraffin-embedded (FFPE) clinical tissue blocks for immunostaining were identified by database search and chart review. Tissue processing and histopathological data interpretation were overseen by an expert gastrointestinal pathologist (J.S.). Where trios of normal colon, primary CRC and metastatic CRC were successfully collected, the patient was longitudinally tracked through their clinical course at MSK using MSK Darwin52, and tumour tissue surplus to diagnostic requirements was collected from any subsequent procedures.

    Patient metadata

    Clinical data, including baseline demographic data and previous treatments (Supplementary Table 1 and Supplementary Fig. 1), were abstracted through manual review of patient electronic medical records by board certified medical oncologists (M.L. and K.G.), collected as part of institutional review board approved protocols (MSK IRB, 14-244 and 22-404). The time to each treatment event was calculated from the date of diagnosis to allow for comparison across patients. Study data were collected and managed using REDCap electronic data capture tools hosted at MSKCC on secure central servers. 17 out of 31 patients had multiple metastatic sites at the time of surgery, and had >50% of tumour sites remaining after surgery. 17 out of 31 patients had early-onset CRC (age of diagnosis, <50 years). Clinical MSK-IMPACT targeted exon sequencing was performed on tumour/normal tissue from 27 out of 31 patients and revealed expected mutations53 (Extended Data Fig. 1b). Consistent with the low percentage (<5%) of metastatic CRC that is mismatch repair deficient/microsatellite instability high, only one patient in our cohort had an microsatellite instability indeterminate tumour. Clinical data collection was censored on 30 September 30 2022.

    Tissue processing

    We collected 50–300 mg of freshly resected surgical tissue in 5 ml of IGFF organoid medium (Advanced DMEM/F12 (AdDF12; Thermo Fisher Scientific), GlutaMAX (2 mM, Thermo Fisher Scientific), HEPES (10 mM, Thermo Fisher Scientific), N-acetyl-l-cysteine (1 mM, Sigma-Aldrich), B27 supplement with vitamin A (Thermo Fisher Scientific)) supplemented with primocin (100 μg ml−1, InvivoGen), plasmocin (50 μg ml−1, InvivoGen), penicillin–streptomycin (100 μg ml−1, Thermo Fisher Scientific), Amphotericin B (2.5 μg ml−1, Cytiva), nystatin (250 U ml−1, Millipore Sigma). For primary and metastatic tumours, specimens were placed into a 15 cm Petri dish using sterile forceps and washed three times with DPBS (Thermo Fisher Scientific) supplemented with the above-described antibiotic cocktail, and minimally chopped with sharp sterile blades to enable transfer of tumour fragments using a pre-wet 25 ml serological pipette.

    Tumour fragments were transferred into a gentleMACS type C tube (Miltenyi) pre-filled with 5 ml of IGFF medium supplemented with antibiotics, DNase I (100 U ml−1, Millipore Sigma) and a commercial cocktail of tissue digestion enzymes (Tumour Dissociation Kit, Miltenyi). Tumours were digested using the gentleMACS Octo Dissociator according to the manufacturer’s 37C_h_TDK_1 protocol for a maximum of 30 min. Considering the heterogeneity of tissue specimens with respect to cell viability, immune infiltration, blood content, necrosis and calcification, the digestion state of the tumour fragments was assessed every 10 min under an inverted microscope. Digestion was interrupted before 30 min if at least 50% of the tumour material appeared broken into clusters of 1 to 10 cells. Next, cell cluster solutions were filtered through a 100 μm cell strainer, and washed three times with DPBS supplemented with antibiotics, with each centrifugation step performed at 100g for 3 min at room temperature. The final cell suspension was filtered through a 100 μm cell strainer, washed and centrifuged for 5 min at 500g and 4 °C.

    Non-tumour tissue was transferred into a 50 ml tube pre-filled with 25 ml dissociation/chelation buffer (8 mM EDTA, 0.5 mM DTT, DNase I (100 U ml−1, Millipore Sigma)). Mucosal fragments were incubated with gentle rotation at 4 °C for a maximum of 30 min. The dissociation state of the tissue fragments was assessed every 10 min under an inverted microscope. Dissociation was interrupted before 30 min if at least 30% of the mucosal material appeared broken into clusters of 1 to 5 colonic crypts. Next, the crypt solution was filtered through a 1 mm cell strainer (PluriSelect) to separate individual crypts or small crypt clusters from large chunks of undissociated mucosa. Dissociation was quenched using an equal volume of DPBS supplemented with antibiotics. At this point, the 1 mm filter was flipped and inverted into a fresh 50 ml tube. Up to 25 ml of DPBS supplemented with antibiotics was flashed through the inverted filter to recover the undissociated mucosal tissue. After manually shaking the suspension of mucosal tissue fragments (approximately 5 times), the collection of clusters of colonic crypts was reattempted as described above. Based on the iteration of filtration and manual agitation steps, up to three additional fractions of crypt suspensions were collected. Crypt suspensions were washed three times with DPBS supplemented with antibiotics, with each centrifugation step carried out at 100g for 3 min at room temperature. Based on visual inspection under an inverted microscope, one or more crypt suspensions were selected for subsequent processing according to the size and integrity of the crypts, and either processed separately or pooled together if individual suspensions were assessed to have low crypt content.

    For both tumour and normal tissue, if blood traces were visible under an inverted microscope, the cell pellet was resuspended in 1–5 ml ACK lysis buffer (Lonza), according to the pellet size and incubated for 5 min at room temperature. Quenching was performed with three volumes of DPBS supplemented with antibiotics, followed by an additional wash to remove ACK traces. The resulting cell pellet was further processed for either scRNA-seq, organoid generation or both. Tissue processing protocols were extensively and iteratively optimized to maximize retrieval of high quality (low mitochondrial and ribosomal content) viable single-cell suspensions for downstream analyses.

    scRNA-seq

    Cell suspensions were filtered through a 40 μm cell strainer and incubated in FACS buffer (10 mM HEPES, 0.1 mM EDTA, 0.1% FBS) with DAPI (1 μg ml−1, Thermo Fisher Scientific) and calcein AM (Invitrogen) for 5 min on ice. Viable (calcein positive) cells were sorted using a 130 μm nozzle (SH800S SONY sorter) and collected in DPBS with 0.04% bovine serum albumin (BSA). scRNA-seq was performed on the Chromium instrument (10x Genomics) according to the 3′ RNA v3.1 user manual. In brief, FACS-sorted cells were washed once with DPBS containing 0.04% BSA and resuspended to a final concentration of 700–1,300 cells per microlitre. Cell viability was above 80%, as confirmed with 0.2% (w/v) Trypan Blue staining (Countess II). Cells were captured in droplets and subjected to reverse transcription and cell barcoding; emulsions were then broken and cDNA was purified using Dynabeads MyOne SILANE followed by PCR amplification according to the manual instructions. Up to 10,000 cells were targeted for each sample. Final libraries were sequenced on the Illumina NovaSeq S4 platform (R1, 28 cycles; i7, 8 cycles; R2, 90 cycles).

    Organoid generation and culture

    Primary and metastatic CRC and normal colon organoid lines were established as previously described10,43,54. Cells processed as described above were centrifuged at 600g for 5 min at 4 °C and resuspended at 2,000 cells per 40 μl of Matrigel. After Matrigel domes solidified at 37 °C, HISC medium supplemented with Y-27632 was added to the wells. Organoids were passaged every 7–10 days, and were considered established after three passages. For non-tumour organoid culture, HISC medium was supplemented with human R-spondin 1 (1 μg ml−1; Peprotech) and NGS-WNT (0.5 M, ImmunePrecise N000). The medium was changed every 3–4 days. Organoid lines were expanded and early-passage stock vials were cryopreserved in liquid nitrogen.

    For validation, organoids underwent targeted exome sequencing by MSK-IMPACT53 and key oncogenic genomic alterations were identified by OncoKB55 (see below). Diagnostic tissue from originating tumours was sequenced to confirm that these alterations were conserved in each derived organoid line. Organoids were verified on the basis of short tandem repeats at the time of establishment and before every experiment, and were routinely tested for mycoplasma contamination (MycoALERT PLUS detection kit, Lonza).

    MSK-IMPACT

    Tumour and organoid targeted exon sequencing was performed using MSK-IMPACT53. The OncoKB precision oncology knowledgebase, an FDA-recognized human genetic variant database curated by experts at MSK55, was used to distinguish between oncogenic alterations (presumed drivers) and variants of unknown significance (presumed passengers). Only somatic alterations labelled as oncogenic, likely oncogenic or predicted oncogenic by OncoKB were included for analysis. The MSK-IMPACT data analysis pipeline is available at GitHub (https://github.com/rhshah/IMPACT-Pipeline). Genomic alterations were annotated with information from OncoKB using the OncoKB annotator tool (https://github.com/oncokb/oncokb-annotator).

    FACETS

    Copy-number alterations in solid tumours were computed from MSK-IMPACT using the FACETS (Fraction and Allele-Specific Copy Number Estimates from Tumour Sequencing) algorithm56, which provides allele-specific copy-number estimates at the level of both gene and chromosome arm. FACETS was also used to generate purity-corrected segmentation files, for detection of whole-genome duplication events, to infer the clonality of somatic mutations, to assess arm-level copy-number changes and to generate mutant allele copy-number estimates.

    Computational data analysis

    scRNA-seq data pre-processing

    Alignment of sequencing reads

    All scRNA-seq datasets were pre-processed as follows: FASTQ files from patient samples were processed with the SEQC (v.2.7.0) pipeline57 using the hg38 human genome reference, default parameters and platform set to 10x Genomics v3 3′ scRNA-seq kit. The SEQC (v.2.7.0) pipeline performs read demultiplexing, alignment and unique molecular identifier (UMI) and cell barcode correction, producing a preliminary count matrix of cells by unique transcripts. By default, the pipeline will remove putative empty droplets and poor-quality cells based on (1) the total number of transcripts per cell (cell library size); (2) the average number of reads per molecule (cell coverage); (3) mitochondrial RNA content; and (4) the ratio of the number of unique genes to library size (cell library complexity). However, due to the sensitivity of the colorectal epithelium to dissociation, we observed increased indicators of cell stress, apoptosis and droplet contamination in many samples, including high mitochondrial and ambient RNA expression, which can obscure statistical inference from meaningful biological gene expression. As such, typical ad hoc cell filtering based on identifying a steep dropoff in the number of transcripts per droplet (that is, a deviation leading to a ‘plateau’ in ambient RNA levels), could impair the extraction of meaningful biology. We therefore sought to systematically evaluate and correct for ambient RNA expression and filter for real single cells using CellBender (v.0.1.0)58 as described below.

    CellBender to subtract ambient RNA

    CellBender (v.0.1.0)58 is an unsupervised method for removing ambient RNA from scRNA-seq data. It first infers levels of ambient RNA and rates of barcode swapping per gene and droplet, respectively, from an unfiltered cell-by-gene count matrix. This probabilistic model is then used to generate a denoised (that is, ambient RNA-corrected) count matrix, as well as the probability that each droplet contains a cell, which can be used for calling real cells. We ran CellBender (v.0.1.0) on the unfiltered count matrix of each sample produced by SEQC (v.2.7.0) with the following parameters: (1) set the expected number of cells as the number of cells loaded into each 10x Chromium lane per sample (typically 5,000–10,000 cells); (2) set total droplets used to estimate ambient background RNA to 30,000; and (3) set training epochs to 100. We used the denoised count matrix produced by CellBender (v.0.1.0) for all subsequent analyses.

    Removal of low-quality cells

    On the basis of CellBender-corrected expression counts, we sought to identify and filter out low-quality cells from downstream analysis. As our study focuses on epithelial cells, which are known to be more sensitive to single-cell dissociation than other cell types, we paid special attention to droplet quality by performing three filtering steps:

    Step 1: remove all droplets with posterior probability of containing cells 0.5 according to CellBender (v.0.1.0). This lenient filtering ensured that no biologically relevant cells were removed, at the cost of retaining some cells with worse technical characteristics. Step 2: remove droplets with <200 total counts, <200 total genes expressed or of which the libraries comprised >50% mitochondrial RNA. Step 3: Iterative rounds of clustering and filtering to remove low-quality or apoptotic cells that group together to create unstructured ‘junk’ clusters. We carried out this filtration by combining count matrices from all patients for each sample type (non-tumour, primary tumour and metastasis), clustering cells using PhenoGraph11 (k = 20), and studying the covariance structure of highly expressed genes within each cluster. We reasoned that highly expressed genes are not co-regulated in cells undergoing apoptosis, nor in droplets containing ambient RNA, motivating the removal of droplets lacking meaningful covariance structure. We repeated the process of clustering and filtering until only cells residing in structured clusters remained, after which all datasets were combined.

    Cells passing all of the above criteria were retained for downstream analysis.

    scRNA-seq data analysis

    Data normalization and dimensionality reduction

    Raw count matrices were normalized to the median library size and log-transformed with a base of e and pseudocount of 0.1. We then selected highly variable genes (HVGs) using the highly_variable_genes function in Scanpy (v.1.9.1) and flavour = seurat_v3 (we chose bins = 40). We kept the top 50 genes within each bin, for a total of 2,000 HVGs. Moreover, for all datasets (besides the fetal colon dataset), we included genes with known relevance to normal colonic cell types (41 genes) and cell states associated with inflammatory disease, injury of the colon, and regulation of REST and EMT (56 genes) (a complete list of genes is provided in Supplementary Table 7). Going forward, we will denote the 2,097 genes including both HVGs and manual additions as HVGs. Next, we performed PCA of log-normalized matrices using only HVGs and retained the number of principal components (PCs) that explain 75% of variance (112 PCs). For all datasets as well, we chose a number of PCs explaining 75% of variance.

    Data visualization

    For all two-dimensional embeddings, we used the Scanpy (v.1.9.1) neighbours function to compute a k-nearest-neighbour graph on the PCs based on Euclidean distance and k = 30. To visualize the global CRC cell atlas (Extended Data Fig. 2b,e,h,i), non-tumour epithelium (Extended Data Fig. 2f) and human fetal gut cell atlas (Fig. 2c), we generated projections using the UMAP implementation in Scanpy (v.1.9.1), with min_dist = 0.3–0.5 and init_pos = paga. To visualize epithelial cell subsets including all untreated epithelial cells (Extended Data Fig. 3a,c), all tumour cells (Extended Data Fig. 5e–j) and patient KG146 cells (Fig. 2a and Extended Data Fig. 9b,c), we used force-directed layouts, which provide a more intuitive representation of cell state transitions and the local relationships between subpopulations, using Scanpy (v.1.9.1) with the ForceAtlas2 layout and init_pos = paga. The Python package matplotlib (v.3.6.0) was used to produce all plots.

    Gene expression denoising and imputation

    We applied MAGIC (v.3.0.0) imputation59 to normalized, log-transformed count matrices to denoise and recover missing transcript counts due to dropout. Imputation was performed using conservative parameters (t = 3, ka = 5, k = 15). Imputed values are used for visualization of gene expression or gene signature expression (described in the main text and figure legends where used), as well as for analysing mixed-lineage gene correlations in untreated patient tumours (see the ‘Gene correlations in normal intestine and untreated tumour’ section).

    Gene signature scores

    To generate all gene signature scores in our study, we used the Scanpy (v.1.9.1) score_genes function, which calculates the mean expression of genes of interest subtracted by the mean expression of a random, expression-matched set of reference genes. To account for expression-level differences across genes within signatures, we provided z-normalized expression data as the input for this function.

    Cell annotation

    Partitioning cells into epithelial, stromal and immune compartments

    We clustered the dataset of all cells using PhenoGraph (v.1.5.7) with the Louvain algorithm (k = 45) on the PCs obtained above. To ensure robustness to the choice of k, we repeated PhenoGraph (v.1.5.7) clustering for all values of k between 20 and 100 in increments of 5 and calculated the adjusted Rand index between each pair of clusterings. We chose the value k = 45, which, within small variation, generated a Rand index > 0.9, indicating that cell assignments to clusters remain mostly unchanged and are therefore robust to the choice of k.

    We next partitioned clusters into epithelial, stromal and immune compartments based on marker gene expression (Extended Data Fig. 3a,b). Specifically, we used the score_genes function in Scanpy (v.1.9.1)60 to score expression of compartment-specific gene signatures from ref. 61, similar to the strategy used in that study (signatures for each compartment are shown in Supplementary Table 7). Each cluster was assigned to the compartment with the maximal score.

    Analysis of the epithelial compartment

    We filtered the epithelial compartment to discard any remaining low-quality cells, by removing the lowest modes in the distributions of log-transformed library-size, log-transformed number of genes expressed and the fraction of mitochondrial RNA, resulting in 67,534 epithelial cells. We chose to assign thresholds separately for each compartment due to their different sensitivities to dissociation and sample preparation, as well as inherent biological differences between compartments, for example, tumour cells often have very large library sizes compared to immune or stromal cells.

    Within the epithelial compartment, we then recomputed HVGs (2,097 HVGs), re-performed PCA (210 PCs, 75% variance explained) and clustered cells with PhenoGraph (v.1.5.7) (k = 30) and removed the four remaining outlier clusters containing cells belonging to patients KG103, KG105 and KG66. These clusters were characterized by a very low library size; little block structure in their gene covariance matrices, primarily containing mitochondrial and ferroptosis-associated genes; and a strong overlap between cells originating from the patients’ non-tumour, primary and metastatic samples. Consistent with our scRNA-seq data, we observed very aberrant mucosa in histological images of non-tumour samples for these patients, noting an association with previous disease conditions, which may explain the poor sample quality. Together, these observations suggested that the clusters probably represent highly stressed or dying, disease-associated cells that would not be informative to our study. After removing them, 47,437 cells remained; all downstream analysis of the epithelial compartment was performed on these cells.

    Tumour cell identification using single-cell CNA calls

    We identified cancer cells in the epithelial compartment (Extended Data Fig. 3c–e) using the following criteria: (1) evidence of copy-number alterations (CNAs) compared with cells originating from non-tumour colon samples; and (2) clustering that is distinct from non-tumour epithelial cells.

    We identified CNAs at the single-cell level using infercnvpy (v.0.4.0), a Python implementation of InferCNV12, using a sliding window of 200 genes and the default parameters. The mean expression of the reference diploid was determined using all available normal tumour-adjacent samples. We performed Leiden clustering on the inferred copy-number matrix and called cancer cell clusters if they had <25% normal tumour-adjacent cells and an average CNA score 1 s.d. from the diploid mean. As a result, 3,102 cells derived from tumour samples with no CNA were reclassified as non-tumour epithelial cells (we performed cell type annotation on these cells in the section below), and 26,145 cells derived from tumour samples with CNA remained classified as tumour cells. We also produced an independent CNA estimate using the FACETS pipeline56 for samples from patients with targeted DNA panel sequencing data. In many cases, patient CNA estimates by FACETS were consistent with the most abundant single-cell CNA profiles computed with InferCNV for the same patients (an example is shown in Extended Data Fig. 3c,d).

    Cell type annotation in the non-tumour epithelial compartment

    To annotate epithelial cell types, we retained the subset of normal epithelial cells (21,297 cells) collected from the adjacent normal samples and those identified as normal from the tumour samples, computed a PC representation (249 PCs) of the resulting log-normalized count matrix, and clustered cells with PhenoGraph (v.1.5.7) using the Leiden option and k = 15 on the obtained PCs. We ensured robustness to the choice of k as described above. This process resulted in 48 clusters of cells, which were annotated into cell type based on two criteria: (1) similarity of mean z-normalized expression to that of canonical marker genes for major colon epithelial cell types (Extended Data Fig. 3g); and (2) GSEA of relevant cell type gene sets from the literature (Supplementary Table 2), based on differentially expressed genes (DEGs) in each cluster compared with the rest, computed using the R package MAST (v.1.16.0)62. GSEA was performed using the Python package gseapy (v.0.14.0)63 with 10,000 permutations and the default parameters. On the basis of both criteria, we manually annotated the clusters as ISC (2,580 cells), absorptive precursor (6,874 cells), enterocyte (2,115 cells), BEST4+ enterocyte (1,367 cells), secretory precursor (5,573 cells), goblet (1,751 cells), tuft (848 cells) and enteroendocrine (189 cells) (Extended Data Fig. 3f–j).

    Comparison of normal ISCs and treatment-naive tumours

    Creation of an ISC-specific gene signature

    To determine ISC-specific marker genes, we performed differential expression analysis of ISC cells against all other non-tumour cells using MAST (v.1.16.0) on the normalized, log-transformed count matrix for non-tumour epithelial cells, and calculated gene rankings according to the −log[P] × log[fold change] value for each gene (Supplementary Table 2). The final ISC gene signature consisted of the top 100 ranked DEGs (P < 0.01 for all genes included; Supplementary Table 2). We calculated a gene signature score on the z-normalized expression of these genes using the score_genes function in Scanpy (v.1.9.1) (Fig. 3c).

    PCA and annotation of PC1

    We took a subset of the single-cell dataset containing all untreated normal and tumour epithelial cells (13,935 cells) and performed PCA of the log-normalized expression matrix. We focused on the first PC (PC1), which we note was responsible for 13.5% of the variance in the dataset (compared to 8.96% of variance described by PC2). To annotate PC1, we ordered all genes according to their feature loadings on PC1, excluding genes with zero-valued loadings which cannot be ordered. Using this ordering, we performed GSEA using the prerank function of the Python package gseapy (v.0.14.0) with relevant cell type gene sets from the literature13,21,61,64,65 (Supplementary Table 3) and the default parameters as inputs (Fig. 3d).

    DEG and GSEA analysis between untreated tumour and ISC cells

    We performed differential expression analysis of ISC cells against all untreated tumour cells using MAST (v.1.16.0) and GSEA using relevant cell type gene sets from the literature (Supplementary Table 3) as well as all Hallmark66 and KEGG67 gene sets (Extended Data Fig. 3f). GSEA was performed using the prerank function of the Python package gseapy (v.0.14.0) with 10,000 permutations and the default parameters (Supplementary Table 3).

    Identification of ISC phenotypic admixture in treatment-naive tumours

    To assess whether the cell type promiscuity observed at the cluster level (Extended Data Fig. 3e) is also present in individual cells, we used MAST (v.1.16.0)62 to compute DEGs enriched in ISCs, enterocytes and goblet cells in the non-tumour epithelial dataset; ranked each DEG by −log[P] × log[fold change] value; and used the top 300 genes as lineage markers (Supplementary Table 3). For enterocytes and goblet cells, DEG analysis was restricted to differentiated cell types (that is, excluding precursor cell types). This allowed genes shared between precursor and differentiated cell types of the same lineage to be recovered by DEG analysis. For example, the expression of enterocyte marker SLC26A3 in late-absorptive precursor cells lowered its observed differential expression in enterocytes compared with all other cells when absorptive precursors were included in DEG analysis, despite abundant SLC26A3 expression among enterocytes.

    As tumour cells do not emulate the complete phenotype of normal differentiated cell types68, we restricted the 300 cell lineage markers from above to genes that are also abundantly expressed in more than 20% of primary tumour or metastasis cells. We consider a lineage marker to be abundantly expressed in a cell if its normalized expression in that cell was greater than or equal to the bottom quartile of expression from the lineage for which it is a marker. To ensure the specificity of markers, we also removed any gene that is abundantly expressed in other lineages. Finally, we determined the fraction of the remaining lineage markers that are abundantly expressed in each normal cell and treatment-naive tumour cell. The distributions for each cell type and tumour type are visualized using the sns.kdeplot function in Python Seaborn (v.0.11.2) (Extended Data Fig. 3h–j).

    Gene correlations in normal intestine and untreated tumour

    To understand whether the co-expression of conflicting cell type markers (Extended Data Fig. 3h–j) is associated with the loss of cell-type-specific gene regulation in tumours, we first computed Pearson correlations between all pairs of top ranking DEGs for ISCs, enterocytes and goblet cells as described above (300 genes total) using the imputed expression matrix for (1) all non-tumour epithelial cells and (2) all treatment-naive tumour cells (Extended Data Fig. 3g). To account for heterogeneity in gene regulation across tumours, correlations were first computed for each patient tumour separately, resulting in 12 correlation matrices, and averaged. In this way, the observed strong correlations correspond to those gene pairs with strong positive or negative correlations across multiple patient tumours, suggesting consistent gene dysregulation compared to the non-tumour setting.

    Identification of Hotspot gene modules in CRC tumour data

    We used Hotspot (v.0.9.1)20, an algorithm for identifying context-specific gene modules within single-cell datasets given a user-provided metric for local cell–cell similarity, to identify shared context-specific gene modules in our patient tumour dataset. Hotspot evaluates the pairwise local correlation between genes in local cell neighbourhoods within the cell–cell similarity (k-nearest neighbours (k-NN)) graph, identifying genes with high local autocorrelation. Importantly, the way significant local autocorrelation is detected is suited to scRNA-seq, and is resilient to issues such as gene drop-out in individual cells. The computed gene–gene affinity matrix is clustered to output a set of gene modules. In contrast to global measures of correlation (such as Pearson’s correlation), which presume relationships between features are consistent across a single-cell dataset, Hotspot’s local correlation measures are computed on the local cell neighbourhoods in the k-NN graph.

    While non-negative matrix factorization has been used to identify cancer gene programs21,22, it is a linear method that requires a consistent and complete decomposition of the entire dataset, and it can be sensitive to batch and other variation. By contrast, Hotspot is based on gene–gene covariance, which better represents sets of genes that work together towards common functions, and is robust to batch effects57 (and is therefore likely to be more robust to variation between tumours). Importantly, Hotspot gene modules are based on covariance that can be localized to a cell subpopulation or exhibit potentially nonlinear graded expression over regions of the manifold. In cancer in particular, heterogeneous cell states adapted to different patient tumour contexts, such as metastatic sites, are likely to correspond to differences in gene covariance. Hotspot is also well suited to handle both gene pleiotropy and rare populations, which have important roles in tumour contexts. We therefore chose Hotspot to characterize sources of inter- and intra-tumour phenotypic heterogeneity in our dataset alongside global, manifold-defining modules of genes.

    To apply Hotspot, we first partitioned the data to only include tumour cells (26,145 cells), and used their top 2,097 HVGs (see the ‘Data normalization and dimensionality reduction’ section above). After renormalization, we performed PCA and retained enough PCs to explain 75% of the variance (233 PCs). We then identified a subset of significantly autocorrelated features with respect to the PC latent space by running Hotspot using the depth-adjusted negative binomial (danb) observation model and 30 neighbours. The danb model69 comprises the background null distribution against which expression counts are normalized, and is used to avoid flagging genes as significant due to local autocorrelation in the library size of cells.

    We retained 2,003 genes with a FDR < 0.01 for calculating local correlations and downstream clustering (see below). We used the create_modules function in Hotspot (default parameters except for minimum_gene_threshold = 20 and core only = False) to obtain a preliminary set of 37 co-varying gene modules (gene assignments to modules are shown in Supplementary Table 4).

    Hotspot module clustering

    Hotspot clusters the gene–gene local correlation matrix into modules using an agglomerative hierarchical clustering procedure that, at each step, merges two genes/modules with the highest pairwise z-scored correlation. Once a merged module contains more genes than a minimum threshold, it is labelled and cannot be combined with other labelled modules. The process ends when the highest pairwise z-score between unmerged modules falls below a minimum value; at that point, all genes that are unlabelled are not assigned to any module.

    In practice, we found that choosing a large value for the minimum gene threshold left too many genes unassigned and created modules that, due to their high numbers of genes, were difficult to interpret. Choosing too small of a threshold failed to merge some intercorrelated, biologically similar modules. We opted to use a lower threshold of 20 genes minimum—to err on the side of more manageable, smaller modules—and then manually group modules with similar biological interpretations, after ensuring their genes were also correlated. This process is described in detail below.

    Hotspot module grouping and annotation

    All original 37 Hotspot modules were annotated manually based on known canonical markers for intestinal and non-intestinal cell types and from the literature (a subset of annotation genes is shown in Fig. 1b and Extended Data Fig. 5b,c, and all annotation genes are shown in Supplementary Table 4). Gene set over-representation analyses using gseapy (v.0.14.0) and the Gene Ontology Biological Process gene sets provided supporting evidence for our initial annotations, or suggested possible directions to investigate for modules that were difficult to annotate (module annotations and over-representation analysis for final module annotations are shown in Supplementary Table 4).

    We focused on 23 out of the 37 modules (1,201 genes) representing meaningful biological gene programs and did not further explore 14 modules (722 genes) annotated as cell cycle/proliferation (2 modules), cell stress (4 modules), leukocyte (3 modules) or cilia (1 module), or else could not be interpreted (4 modules). We then manually grouped 19 modules into 6 groups after (1) arriving at the same biological interpretation for all modules within a group, and (2) ensuring the local correlations between genes of grouped modules were high on average (Extended Data Fig. 5a,b). These six grouped modules and four single modules resulted in ten final gene modules (Extended Data Fig. 5a,b and Supplementary Table 4).

    Once the modules were annotated and grouped using the above-described strategies, we categorized them into two distinct categories:

    1. (1)

      Canonical: modules describing canonical intestinal cell types and processes such as epithelial differentiation, mucus production and small-molecule transport, which are critical for maintaining normal intestinal function.

    2. (2)

      Non-canonical: modules describing processes not typically seen in healthy intestine, such as keratinization, inflammatory response and wound healing.

    Hotspot gene module scores

    Hotspot modules scores were calculated for our tumour dataset using Hotspot’s calculate_module_scores function. In brief, Hotspot evaluates per-cell scores for each module using the following procedure: for all genes in a module, expression counts are first mean-centred using the danb null model and smoothed using the weighted average of their nearest neighbours. The background null distribution factors cell library size differences into account; thus, centring based on the null ensures that correlations are not impacted by library size differences. PCA is then performed on the resulting centred counts and the first PC values are used as the module scores for each cell. We used Hotspot module scores to visualize and summarize the patterns of module expression within cell groupings (for example, clusters), and to relate gene modules to gene signature scores for pre-existing gene sets as well as to sample metadata.

    To plot groups of cells with top-scoring expression for a given module, we used the scanpy dotplot function (Extended Data Fig. 5b,c). To assign cells as top-scoring for a Hotspot module, we z-normalized all Hotspot module scores across cells, and then required a top-scoring cell to very specifically express a given Hotspot module and not express any others. To ensure this, we required top-scoring cells to have (1) a score of >1 s.d. above its mean module score, and (2) a score of <1 s.d. above the mean for all other modules (cells are assigned to 1 out of the 23 ungrouped modules on which we focus in Extended Data Fig. 5b and to 1 out of the 10 grouped modules in Extended Data Fig. 5c). We found these criteria to be more selective than, for example, the percentile scores used in other sections when identifying cells that are high for a given module.

    Robustness of Hotspot modules

    We evaluated the robustness of the Hotspot analysis to the number of HVGs used as input features, based on the consistency of gene autocorrelation, and the consistency of obtained modules. We also evaluated the robustness of the Hotspot modules to bootstrapping of cells.

    Consistency of gene autocorrelation to number of HVGs: we evaluated whether the input cell–cell similarity matrix faithfully captures the structure of the data across input features (highly variable genes). Given an input gene set, Hotspot removes genes with low autocorrelation along the k-NN graph, ensuring that only genes that vary along the manifold in an informative manner are selected for module detection. To determine whether genes passing this criterion are robust to the number of selected HVGs, we recomputed modules with 1,000–5,000 HVGs in increments of 500 genes, keeping all other parameters constant. For each combination, we calculated the difference in Hotspot local autocorrelations for each gene against its autocorrelation score when we input 2,000 HVGs (the value used in this study) and visualized the average as a box plot (Supplementary Fig. 2). These differences are minimal across Hotspot runs for all HVG pairs (maximum difference of 0.07), suggesting that the cell similarity graph retains its structure regardless of how many HVGs are chosen.

    Consistency of modules to number of HVGs: to verify that the set of genes comprising each module is robust to the number of features, we generated Hotspot modules for 1,500–2,500 HVGs in increments of 50 genes, with minimum_gene_threshold set to 20 and core_only set to false. We then calculated Pearson correlations between the module scores of each set of Hotspot modules and the set obtained with 2,000 HVGs, as used in this study. For each original Hotspot module obtained with 2,000 HVGs, we report the correlation of the module used in this study and the best-matching module—the module that is most highly correlated with the original module in this study (Supplementary Fig. 2). In general, every set of gene features identified a subset of modules showing close correspondence to our final set of modules based on max correlation.

    Robustness of Hotspot gene modules to cell downsampling: to determine whether Hotspot modules depend on the exact cells used as input, we used a bootstrapping-like approach. We randomly resampled our tumour dataset ten times, with 1–10% of cells removed (in increments of 1%) and with 10%, 15% or 20% of cells removed. For each resampling, we calculated new PCs and a new k-NN graph, and reran Hotspot with the same genes and identical parameters as in our main analysis. We then evaluated the similarity of each Hotspot analysis with our original analysis as the maximal difference in local correlations (that is, the difference between the highest and lowest local correlation values across the matrices being compared) (Supplementary Fig. 2). We used this approach because cells cannot be resampled with replacement from a k-NN graph.

    Relationship of Hotspot results to global correlation: while Hotspot gene–gene correlation is only evaluated on cell subsets, the subsets are highly constrained to the neighbourhood structure of the k-NN graph, which is a strong structural feature of the data, and makes it unlikely that Hotspot will find spurious modules. Nevertheless, we expect that these modules will also result in detectable levels of global Pearson correlation. For visual comparison, we plotted pairwise Pearson gene correlation against z-scored pairwise Hotspot local correlation on the log-normalized expression matrix (Supplementary Fig. 2), revealing that the ranking of weak and noisy global signals detected by global correlation largely align with the robust signals sensitively detected by Hotspot. Averaging all pairwise correlations within grouped modules likewise reveals that correlation and global correlation are qualitatively similar (Supplementary Fig. 2).

    Distribution of module expression among samples

    To determine the distribution of cells with high expression of the ten Hotspot modules on a per-patient basis, we first labelled a given cell with a gene module if it had >0.75 quantile expression score for that module, then plotted the cumulative fraction of labelled cells for all modules in each tumour sample (Fig. 1c), or in pooled primary and metastatic samples per patient (Extended Data Fig. 6g). Cumulative fractions can exceed 1 as a cell can exhibit high expression of more than a single module.

    We also visualized non-canonical or canonical module prevalence (Fig. 1d,e) as the log-ratio of labelled cell fractions in metastatic to patient-matched primary tumours. Canonical and non-canonical module classifications are described in the ‘Hotspot module grouping and annotation’ section. Although cells can exhibit high expression of multiple canonical or multiple non-canonical modules, we found that they do not often express both canonical and non-canonical modules highly (Supplementary Fig. 2); thus, we labelled cells as non-canonical or canonical according to which classification they score highest (for example, a cell of which the maximum module score is squamous is labelled non-canonical).

    We calculated significance values for these plots using the following strategy: For each binary labelling of cells (for example, non-canonical or not non-canonical), we randomly permuted the labels 1,000 times within each patient separately. For each random permutation, we calculated the log-ratios of positive cells (for example, non-canonical) in metastases to positive cells in primary tumours, as above. We then performed a rank-sum test comparing our original log-ratios to the combined log-ratios from the random permutations. The alternative hypothesis is that our sample distribution is greater than the null (for example, metastasis is higher).

    Interpatient entropy of gene modules

    We used entropy to evaluate the patient-specificity of each Hotspot module using the following procedure: (1) sample 357 cells per patient with replacement in our tumour dataset to ensure even cell distribution across patients. (2) For each module, determine the subset of high-scoring cells with module scores greater than 1 s.d. above the mean. (3) Compute the Shannon entropy of patient labels in the high-scoring subset of cells for each module using the SciPy (v.1.9.1) function scipy.stats.entropy. To calculate the Shannon entropy, we first built a k-NN graph with k = 60 on the multiscale space embedding of all epithelial cells; multiscale space was computed on the top 19 DCs (chosen by the knee-point of DC eigenvalues) using Palantir (v.1.2). Steps 1–3 were repeated 100 times before visualizing the entropy distribution with kernel density plots using the kdeplot function in Python Seaborn (v.0.11.2) (Extended Data Fig. 5d).

    Association of gene modules with clinical covariates in bulk RNA-seq data

    To test the association of each Hotspot modules with clinical covariates in bulk cohorts, we (1) ran single-sample GSEA on two bulk RNA-seq datasets, LARC and TCGA-COAD, collected from CRC patient primary tumours using the genes in our Hotspot modules as the input gene sets; and (2) for each dataset, tested the association of patients’ clinical features with the enrichment scores of their tumour samples.

    ssGSEA analysis

    For LARC, we analysed 108 LARC tumour samples with available RNA-seq data32. Genes were retained if they had >1 count per million across more than 50% of the samples. The edgeR v.3.40.2 package70 was used for trimmed mean of M-values normalization and FPKM transformation and the org.Hs.eg.db v.3.16.0 package was used for gene annotation. Genes that mapped to multiple Ensembl IDs were removed. We then performed ssGSEA analysis using the hacksig v.0.1.2 R package30 and all Hotspot modules. In this cohort, 0.4% of patients have a survival status of alive and an overall survival (OS) follow-up time of <12 months (0% with OS follow-up of <6 months); 1.7% of patients have no distal recurrence and a disease-free survival (DFS) follow-up time <12 months (0% with DFS follow-up of <6 months).

    For TCGA, we downloaded and analysed RNA-seq data for 445 tumour samples from the TCGA-COAD study31. RNA raw counts were retrieved using TCGAbiolinks (v.2.26.0)71 and genes with a count of 0 across all the samples were removed, as well as genes that had multiple associated gene symbols or no gene symbol. The VST transformation was performed using the DESeq2 (v.1.38.3) package72. Subsequently, ssGSEA analysis was conducted utilizing the R package GSVA (v.1.46.0)73. In this cohort, 13% of patients have a survival status of alive and an OS follow-up time of <12 months (7% with OS follow-up of <6 months); 0.9% of patients have no new tumour event and a DFS follow-up time of <12 months (0.7% with a DFS follow-up of <6 months).

    Associations with clinical covariates

    For binary clinical features, we separated the enrichment scores into two groups based on the status of the patient from which the bulk RNA-seq data were collected and compared the enrichment scores for each Hotspot module between the two groups using the Mann–Whitney U-test (Fig. 1f,g and Extended Data Fig. 6h–j).

    Survival analyses in TCGA-COAD cohort

    For each Hotspot module, we collected two groups of samples from the TCGA-COAD cohort: (1) highly enriched samples with ssGSEA enrichment scores greater than 1 s.d. above the mean enrichment score among all samples, and (2) low-enriched samples with enrichment scores less than 1 s.d. below the mean. We then performed a log-rank test on DFS between these groups using the lifelines (v.0.27.4) package in Python74. We generated survival curves for all modules with significant results (P < 0.05) (Extended Data Fig. 6k). Multivariate logistic regression models were used to evaluate associations between DFS, OS and module expression. Each sample was annotated as high or low for each signature based on an ssGSEA score >0.75 s.d. above or below the mean, respectively. Samples without the signature annotation were excluded from the analysis. Cox proportional hazards tests were used for multivariate analysis of DFS. We generated forest plots for all modules with significant results (P < 0.05) (Supplementary Fig. 3). R packages survival (v.3.6-4) and survminer (v.0.4.9) were used for the survival analysis.

    Delineation of canonical to non-canonical tumour axes across patients

    To characterize trends in cancer progression, we analysed the four patients with a sufficient number of cells in non-canonical states for robust characterization, namely KG146 (3,351 cells), KG182 (935 cells), KG183 (1,203 cells) and KG150 (2,574 cells). We reprocessed each patient individually to most faithfully capture trends within each individual patient; data from primary tumour, synchronous metastatic tumour and metachronous metastatic tumour samples were pooled for each patient and processed as described in the ‘Data normalization and dimensionality reduction’ section. We used DC analysis, which identifies the largest axes of nonlinear variation in the data and has been shown to effectively capture cell-state transitions in scRNA-seq data75. DCs were independently computed for each patient to separately compute potential per-patient routes of tumour progression and to avoid artificially imposing the trends from patients with large samples on patients with smaller samples.

    We computed diffusion maps (k = 30 nearest neighbours) for each patient and retained a subset of DCs based on the eigengap of the ranked components’ eigenvalues (KG146, 4; KG182, 6; KG183, 8; KG150, 4 DCs). The strongest DCs appear to define a continuum from canonical to non-canonical fates. Thus, we ranked the DCs of each patient by the difference between the average Spearman correlation of a given DC with (1) all non-canonical modules and (2) all canonical modules; the greatest difference between the two averages defines an axis for canonical to non-canonical transformation (Fig. 2b and Extended Data Fig. 7a). For KG146, KG182 and KG150, the first DC was selected, while the fourth DC was selected for patient KG183. The consistent and independent selection of the first DC as the canonical to non-canonical transition in 3 of 4 patients supports the importance of this axis as one of the strongest signals in the data. We note that KG183 had fewer non-canonical cells than the other patients, probably explaining why this transition was not the top DC for this patient. We used the progressive nature of our samples (normal to primary to metastasis) to reason that—as normal included only canonical, and metastasis contained the largest fraction of non-canonical cells—this axis indeed represents a cell-state progression.

    Visualization of module trends

    We used generalized additive models (GAMs) with cubic splines as smoothing functions as in Palantir (v.1.2)42 to analyse module score trends along DC axes (Fig. 2b and Extended Data Fig. 7a). GAMs increase robustness and reduce sensitivity to density differences, and cubic splines are effective in capturing non-linear relationships. We fitted trends for a module score using a regression model on the DC values (x axis) and module score values (y axis or colour intensity). The resulting smoothed trend was derived by dividing the data into 500 equally sized bins along the DCs and predicting the module score at each bin using the regression fit. We visualized module score trends from the 20th percentile value (white) to the maximum value (highest saturation) (Fig. 2b and Extended Data Fig. 7a).

    Derivation of a human fetal colon progenitor gene signature

    We used a fetal gut cell atlas containing scRNA-seq data from dissected human embryos aged 6.1 to 17 weeks, which captures the development of human intestinal cells from a fetal progenitor state to differentiated crypts40. We downloaded a raw H5AD file from the authors containing all epithelial cells from fetal donors and limited our analysis to 8,408 cells originating from the large intestine of first and second trimester samples.

    Data reprocessing and DEG analysis

    As large intestine cells represent a minority of the fetal gut cell atlas (8,408 of 52,184 total cells), we partitioned and reprocessed the dataset to focus our analysis on these cells. We ran HVG selection (2,000 HVGs), PCA (167 PCs explaining 75% variance) and UMAP projection (min_dist = 0.5) using scanpy as described in the ‘Data normalization and dimensionality reduction’ and ‘Data visualization’ sections. UMAP projection revealed that the week 11.1 sample separated from all others. Cells from this sample were characterized by heat-shock genes DNAJB1, HSP90AA1, HSPE1, HSPA8 and HSPA1A among the top 10 DEGs (compared to all other samples, by MAST analysis) indicating cell stress, so it was removed, resulting in 7,984 cells. In the remaining dataset, we retained the authors’ original cell type annotations, but merged the enteroendocrine subtypes (M/X, D, β, L, N, K, I and enterochromaffin cells) into one group.

    We found that the first trimester samples consist predominantly of progenitor cells; proximal progenitor, distal progenitor and stem cells comprise 88% of all cells. By contrast, second-trimester samples consist of mature colon mucosal cell types exclusively, and exhibit strong expression of LGR5, TFF3, SLC26A3, NEUROD1 and POU2F3 (corresponding to ISCs, goblet cells, mature enterocytes, enteroendocrine and tuft cells, respectively). We therefore concluded that the separation between the first- and second-trimester samples captures the distinction between progenitor-like cell types and colonic crypts.

    To determine marker genes specific to the first trimester cell population, we performed a differential expression analysis of first versus second trimester cells using MAST (v.1.16.0) on the normalized, log-transformed count matrix and identified 173 DEGs with log[FC] > 2 and adjusted P < 1 × 10−5. Earlier cells are more proliferative, so we removed genes related to cell cycle or proliferation from our first-trimester gene list. Specifically, we calculated the Pearson correlation of all first trimester DEGs with 445 genes belonging to the Reactome ‘Cell Cycle, Mitotic’ and ‘Cell Cycle, G1-G1/S Phase’ gene sets and the Hallmark ‘Cell Cycle, G2M Checkpoint’ gene set76. We removed 60 genes with a correlation greater than 0.25 for at least one gene belonging to the gene sets. Our fetal gene signature comprises the remaining 113 genes (Supplementary Table 5).

    Comparison with existing dedifferentiation signatures

    We compared our 113-gene fetal signature to previously published dedifferentiation signatures23,34,38,39. For each pair of signatures, we calculated the Jaccard index (number of genes shared between signatures divided by total number of genes in both signatures), demonstrating that existing signatures are clearly distinct from our fetal signature and lack consensus (Extended Data Fig. 7b). We also determined how many of the 14 core fetal signature genes (see the next section) are present in each dedifferentiation signature, normalized to the total number of genes in that signature.

    For each of the three major progenitor cell populations in first trimester dataset, and the five major populations in the second trimester dataset described above, we calculated the average score of the various signatures (see the ‘Gene signature scores’ section), finding that our fetal signature is clearly enriched in first trimester and depleted in second trimester populations, whereas other signatures lack coherent enrichment trends (Extended Data Fig. 7c).

    Mapping fetal signature along tumour progression axis

    For each patient, KG146, KG182, KG183 and KG150, we calculated gene set scores using the scanpy function score_genes and the list of 113 genes in our fetal signature. We determined which genes in our fetal signature are correlated (Pearson r > 0.5) with the fetal signature score trend along the major diffusion component, as in the ‘Identification of fetal-state-associated transcription factors’ section below (Extended Data Fig. 7d). Among the 113 genes of the fetal signature, 88 genes are strongly correlated in at least one patient; 59 in at least two patients; and 37 in at least three patients, with a large number of genes correlated for each patient (56 in KG146, 51 in KG182, 29 in KG150 and 62 in KG183). Moreover,14 are strongly correlated with the signature score in every one of the four patients, forming a ‘core signature’ of candidates for driving fetal state reversion in patient tumours. We calculated a gene set score using these 14 core genes, as well and a significance value was calculated for its distribution among samples as in ‘Distribution of module expression among samples’ above (Extended Data Fig. 7e).

    Kaplan–Meier analyses of fetal signature in bulk data

    For all of the samples in the LARC and TCGA-COAD cohorts, we calculated ssGSEA enrichment scores as described in the ‘ssGSEA analysis’ section using our fetal gene signature as input. For each cohort, we then collected (1) highly enriched samples with ssGSEA enrichment scores >1 s.d. above the mean enrichment score among all samples; and (2) lowly enriched samples with enrichment scores <1 s.d. below the mean. We performed a log-rank test on DFS between these groups using the Python lifelines (v.0.27.4) package (Extended Data Fig. 7g,h).

    Pseudo-ordering of cell states by module overlap

    Although diffusion component analysis orders patient cells along transitions from canonical to non-canonical fates in a reproducible and unbiased way, it is less effective in patients whose tumours have few cells in non-canonical states. As an alternative, we consider the observation that in most cell-state trajectories, gene modules tend to be co-expressed in the same cells if they define pairs of sequential cell states. Using this logic, the existence of a substantial fraction of cells co-expressing two distinct gene modules can be used to suggest a pseudo-ordering of these states, and a transition between them. A key feature of Hotspot is that a cell can co-express multiple modules (Fig. 1b and Supplementary Fig. 2), making it possible to examine cells occupying mixed states. To ensure that we only consider robust module expression, we assigned a cell to a module if it expresses module genes above the 75th percentile. For all pairs of Hotspot modules, we computed the fraction of modules that are co-expressed in the same cell, and we aggregated across patients due to the sparsity of some cell states in any given patient. This analysis reveals a progression (block diagonal) that agrees with DC analysis of the four patients with non-canonical states (KG146, KG182, KG183 and KG150) and is consistent across these four patients (Fig. 2d), the full cohort with these four patients removed (Fig. 2e), and five patients from an independent dataset (Fig. 2f).

    Replication in an independent CRC scRNA-seq dataset

    The scRNA-seq dataset from ref. 28 consists of matched primary tumour and liver metastasis samples for each of five patients who received multiple cycles of chemotherapy. We downloaded GEO accession GSM7058755 (colorectal cancer, nonimmune cells) comprising all tumour and stromal cells from these patients. We first filtered all cells with >40% mitochondrial UMIs or <1,000 UMIs, leaving 23,341 cells. We normalized data and classified epithelial cells using the same methods described for our data in the ‘scRNA-seq data analysis’ and ‘Cell annotation’ sections; in brief, each PhenoGraph (v.1.5.7) (k = 30) cell cluster was classified according to the highest average score across all cells for a broad panel of stromal and epithelial genes. Only these filtered epithelial cells were used in downstream analyses.

    Hotspot module analyses differ between our dataset and the ref. 28 dataset in two ways. First, gene module scores in our dataset are calculated using the k-NN graph that was generated to run Hotspot (see the ‘Hotspot gene module scores’ section), whereas the ref. 28 dataset requires its own k-NN graph, rendering the results impossible to compare. Instead, we calculated gene set scores using the scanpy function score_genes and the list of genes for each Hotspot module. Second, in our dataset, we used 0.75 quantile score thresholds to quantify per-patient cell abundances of Hotspot modules (Fig. 1b). As these are relative thresholds, repeating the analysis in the ref. 28 dataset would not account for the possibility that module genes are expressed at lower levels in ref. 28 compared with our tumour dataset. For this reason, we chose to construct thresholds which specifically reflect the level of expression in our dataset where we know these modules are expressed. To do so, we combined the two datasets and renormalized (median library size normalization and log-scale expression) to the same level of expression. Gene set scores were calculated on the joined, renormalized datasets using score_genes and the 0.75 quantile cut-offs were based only on the cells from our dataset, so that thresholds would reflect the level of expression in our dataset and be applicable to the data from ref. 28. These thresholds were used in Extended Data Fig. 6g.

    Palantir pseudotime and branch calculations

    The four patients whose tumours include the most cells with non-canonical fates (KG146, KG182, KG150 and KG183) span the spectrum of progression, and all contain both squamous and neuroendocrine states. We used Palantir (v.1.2)42 to investigate these two fates and the genes underlying their respective fate transitions. As an input, Palantir requires an initial state, and as the output, it computes terminal fates and provides a cell-fate map that assigns a probability for each cell to differentiate into each terminal fate. Palantir also outputs a pseudotime alignment of cells from the initial to each of the terminal states and, therefore, by combining pseudotime and fate probability for each cell, it can provide branching gene trends leading to each terminal fate (by weighing the contribution of each cell to the gene trend based on the fate probability). Palantir was run separately on the tumour datasets of patients KG146, KG182 and KG150, excluding KG183 because of an insufficient number of non-canonical cells in this patient. We selected cells with the highest imputed expression of LGR5 as the initial state, motivated by their identification as cells of origin in CRC studies. Notably, Palantir has been shown to be robust to the exact choice of starting cell. Running Palantir with 500 waypoints and an eigengap-based number of DCs (6 for KG146, 4 for KG182 and 8 for KG150) yielded distinct branching trajectories from the LGR5+ state to two CDX2 (non-intestinal) terminal cells in all three patients. We disregarded three additional branches in KG146 and KG150 that probably represent canonical-state trajectories, as the terminal cells express CDX2 and differentiated intestine markers including FABP1 and TFF3.

    To annotate the two non-canonical terminal states, we compiled known squamous and neuroendocrine cell markers observed in healthy cells or non-CRC cancers, and calculated the Pearson correlations between their imputed expression and non-intestinal branch probabilities (Extended Data Fig. 8a,b). We excluded all cells with a probability of <0.5 for a given branch when calculating correlations, to avoid interference by cell states outside that branch. This analysis identified branches to neuroendocrine-like and squamous-like states in each patient (a representative example for KG146 is shown in Extended Data Fig. 8a). To further support our annotations, we calculated Pearson correlations between the non-intestinal branch probabilities in each patient and imputed expression for all genes observed in all three patients. We found that the top 5 genes ordered by average correlation among the three squamous branches in KG146, KG182 and KG150 are associated with squamous epithelium and keratinization (DMRTA1, NECTIN4, DLX3, CXCL14, LYPD3), and 4 out of the top 5 genes among the three neuroendocrine branches are associated with glial and neural cells (TRPM3, ITPR2, PLPPR1, PPFIA2) (Supplementary Table 5).

    Palantir gene trends were visualized as described in the ‘Visualization of module trends’ section using generalized additive models to fit gene expression along Palantir-computed pseudotime (Extended Data Fig. 8c). All expression trends for individual genes were calculated on MAGIC-imputed data (see the ‘Gene denoising and imputation’ section), and the s.d. of each expression bin was represented by the s.d. of the residuals of the fit.

    Cell state classifications in KG146 patient tumours

    To annotate KG146 tumour cells, we first analysed primary tumour data (880 cells) by determining PCs that explain 75% of the variance (119 PCs) and using PhenoGraph (v.1.5.7) (k = 30) to identify six clusters. Repeating this process for the liver metastasis (1,279 cells, 200 PCs) yielded nine clusters. We directly transferred all Hotspot gene module scores from our complete tumour dataset to the KG146 tumour cells, calculated the average Hotspot gene module scores for each cluster and annotated the clusters as ISC-like, absorptive-like, secretory-like, fetal, injury repair, neuroendocrine-like and squamous-like based on high scores for specific gene modules associated with respective labels (Extended Data Fig. 9b,c). This resulted in four ISC-like clusters, one fetal/injury repair cluster and one secretory-like cluster in the primary tumour data, and two ISC-like clusters, one absorptive-like cluster, one secretory-like cluster, two fetal/injury repair clusters, one neuroendocrine cluster and two squamous clusters in the liver metastasis data. In both datasets, we further reclassified one cluster of ISC-like cells as TA/Proliferative-like based on their unique expression of the proliferation markers such as MKI67 and PCNA.

    We plotted groups of cells by PhenoGraph (v.1.5.7) cluster (column) and Hotspot module scores (row) using the scanpy dotplot function, with cluster assignments generated within each sample using k = 30 (Extended Data Fig. 9d).

    Normalizing and scoring gene sets in organoid data

    To ensure module and fetal signature scores (Extended Data Figs. 9d and 10a,c,d) were comparable across datasets, we joined our original HISC, IGFF and irinotecan-treated organoid and KG146 patient tumour datasets and normalized the combined data as described in the ‘Data normalization and dimensionality reduction’ section. We then z-scored the log-normalized gene expression matrix across cells and calculated gene set scores on this matrix using the score_genes function in scanpy using lists of genes for each module and the list of fetal signature genes. The shPROX1 organoid datasets were normalized as described in the ‘Data normalization and dimensionality reduction’ section independently of this dataset.

    Mapping organoid data to patient tumour

    To map cells of each organoid sample to the phenotypically closest tumour cell state from the full KG146 patient dataset, we developed a manifold-based classifier that combines Harmony77, a framework for connecting scRNA-seq data using an affinity matrix augmented by mutual nearest neighbours between datasets, and PhenoGraph11 to transfer labels between datasets. We performed the same analysis on each organoid sample individually along with the relevant matched primary or metastatic patient sample, including original (Fig. 3b), irinotecan-treated (Extended Data Fig. 5b) and shPROX1 (Fig. 4a) samples. The process involves three distinct steps—feature selection, co-embedding and classification. The resulting numpy matrices were concatenated to obtain an ‘augmented’ cell–cell affinity matrix that consists of three main components: (1) similarity between in vivo cells; (2) similarity between in vitro cells; (3) similarity between in vitro and in vivo cells.

    Feature selection

    We identified the top 100 DEGs for each annotated cell state in the KG146 patient tumour dataset, resulting in a total of 800 genes. We then partitioned the resulting lists to retain the subset of highly significant genes with log[FC] > 3 and Benjamini–Hochberg-adjusted P < 0.001, resulting in 753 genes total. These genes were used for PCA and to produce neighbour graphs in the following steps.

    Co-embedding

    As expected given the differences between in vivo and in vitro data, using a standard co-embedding approach consisting of a joint PCA and UMAP, we observed extreme batch effects between the two datasets, making label transfer between similar cells ineffective. We therefore followed the approach outlined previously45 to bridge between datasets. We first computed the nearest neighbour graph (Scanpy neighbours function with k = 30) in each dataset separately, then computed mutual nearest neighbours (MNNs) between the samples using Harmony77. Importantly, we used the cosine metric to quantify the distance between cells across samples, as this metric is less sensitive to technical artifacts and better reflects conserved biological states in both in vivo and in vitro samples78. We chose a higher number of mutual neighbours (k = 60) because it is more robust to sparsity in the MNN graph.

    Next, the within-sample nearest neighbour and between-sample MNN graphs were converted to within-sample and between-sample affinity matrices, respectively, using the adaptive Gaussian kernel (default parameters) as implemented in Harmony77. The resulting matrices were concatenated to obtain an augmented cell–cell affinity matrix that consists of three main components: (1) similarity between in vivo cells; (2) similarity between in vitro cells; and (3) similarity between in vitro and in vivo cells. This matrix was input to PhenoGraph (v.1.5.7) classification (see below) to propagate labels from the reference (KG146) dataset to the unlabelled dataset (organoid) and generate UMAP co-embeddings of patient and organoid datasets.

    Classification

    Finally, we supplied the augmented affinity matrix from step 2 to the PhenoGraph (v.1.5.7) classify function11 with the default parameters. This function converts the affinity matrix into a row-normalized Markov matrix and computes the probability of random walks starting from unlabelled cells from the in vitro samples, and reaching a class of labelled cells in the in vivo sample. Finally, each unlabelled cell is assigned the cell-state label with the maximum probability.

    Given the large differences between the in vitro and in vivo samples, we wanted to summarize our classification using coarser cell typing. Thus, to summarize our organoid sample classifications, we aggregated the probabilities of different cell states into three generalized categories; ISC-like, combining TA/Proliferative for ISC/TA, absorptive-like and secretory-like for differentiated intestine, and combining fetal/injury repair, neuroendocrine and squamous for non-canonical. These groupings can be interpreted as the likelihood of a cell belonging to any of the several cell states which were combined. The probabilities for each resulting categories are plotted using the python-ternary (v.1.0.8)79 package (Fig. 3b and Extended Data Fig. 10b).

    Identification of fetal-state-associated transcription factors

    We aimed to generate a ranked list of human transcription factors that are associated with the fetal progenitor state in a conserved manner across non-canonical patient tumours. Starting with a list of 1,665 human transcription factors80, we restricted potential targets to transcription factors for which we observe (1) greater than 10 UMIs total in all four patient datasets (leaving 1,099 transcription factors); (2) at least 5 UMIs in any cell in all four patient datasets (leaving 527 transcription factors); and (3) at least 50 transcription factor-expressing cells in all four patient datasets (leaving 508 transcription factors). This filtering was intended to remove sparsely expressed transcription factors that may not be as easily targeted, and to restrict our analysis to transcription factors that are more reliably correlated with our fetal signature.

    Next, we used Palantir to compute expression trends for all the transcription factors and the fetal progenitor signature score along the canonical-to-non-canonical DC (see the ‘Delineation of canonical to non-canonical tumour axes across patients’ section). As we are interested in transcription factors that drive the transition from canonical to fetal cell states, we focused on those with peak expression just prior to entering non-canonical states along the DC of each patient. For patients KG146, KG182, KG150 and KG183, we first identified the position along their DC of the first maxima of the trend in the fetal progenitor signature calculated along this DC (indicated by the vertical dashed lines in Extended Data Fig. 7a). Maxima were identified as the first inflection point along the first derivative of the trend (that is, when the derivative first changes from positive to negative). Trends for KG150 and KG183 lack a first-derivative inflection point, so we used the position of the maximum value for these patients. We then calculated the Pearson correlation between the expression of each transcription factor and the fetal progenitor gene signature score using only cells at positions along a patient’s DC which precede the signature score peak. This yielded four correlation values total for each transcription factor, one for each patient. We focused only on transcription factors with a minimum correlation of r = 0.5 in patient KG146 (leaving 14 transcription factors) and r = 0.2 in all four patients (leaving 5 transcription factors).

    For the remaining six transcription factors, we determined their treatment response in HISC-grown organoids by computing the log-transformed fold change between irinotecan-treated and untreated conditions. log-transformed fold changes were calculated from single-cell data only using cells classified as non-canonical (see the ‘Mapping organoid data to patient tumour’ section) (Extended Data Fig. 11b).

    Multiplexed immunofluorescence

    Multiplexed tissue staining and imaging

    To maximize capture of all areas of the tumour including the invasion front, full clinical pathology sections prepared for clinical diagnosis were used for imaging (not core punches as typically used for tissue microarrays). Primary antibody staining conditions were optimized using standard immunohistochemical staining on the Leica Bond RX automated research stainer with DAB detection (Leica Bond Polymer Refine Detection, DS9800). Using 4 µm FFPE tissue sections and serial antibody titrations, the optimal antibody concentration was determined followed by transition to a seven-colour multiplex assay with equivalency. Optimal primary antibody stripping conditions between rounds in the seven-colour assay were performed following one cycle of tyramide deposition followed by heat-induced stripping (see below) and subsequent chromogenic development (Leica Bond Polymer Regine Detection, DS9800) with visual inspection for chromogenic product with a light microscope (T.J.H.). Multiplex assay antibodies and conditions are described in Supplementary Table 8.

    Seven-colour imaging assay

    FFPE 4 µm tissue sections of were baked for 2.5 h at 63 °C in vertical slide orientation with subsequent deparaffinization performed on the Leica Bond RX followed by 30 min of antigen retrieval with Leica Bond ER2 followed by six sequential cycles of staining with each round including a 30 min combined block and primary antibody incubation (Akoya antibody diluent/block ARD1001EA), except for HER2, which required a 1 h incubation. From each tissue section, we captured around nine fields of view (FOVs) on average, each 1.34 mm2 in size.

    For chromogranin A and OLFM4, detection was performed using a secondary horseradish peroxidase (HRP)-conjugated polymer (Akoya Opal polymer HRP Ms + Rb ARH1001EA; 1:5, 10 min incubation). Detection of all of the other primary antibodies was performed using goat anti-rabbit Poly HRP secondary antibody (Invitrogen, B40962, 1:100, 10 min incubation). The HRP-conjugated secondary antibody polymer was detected using fluorescent tyramide signal amplification using Opal dyes 520, 540, 570, 620, 650 and 690 (Akoya, FP1487001KT, FP1494001KT, FP1488001KT, FP1495001KT, FP1496001KT, FP1497001KT). The covalent tyramide reaction was followed by heat-induced stripping of the primary–secondary antibody complex using Akoya AR9 buffer (AR900250ML) and Leica Bond ER2 (90% AR9 and 10% ER2) at 100 °C for 20 min preceding the next cycle (1 cycle of stripping for HER2 (1 μg ml−1, CST, D8F12), CDX2 (0.46 μg ml−1, CST, D11D10), TP63 (0.15 μg ml−1, CST, D9L7L), PLCG2 (0.2 μg ml−1, CST, E5U4T) and chromogranin A (2.705 μg ml−1, Abcam, EP1030Y); 2 cycles for SOX2 (1.26 μg ml−1, Abcam, SP76), CK20 (0.208 μg ml−1, CST, D9Z1Z), VIM (0.0375 μg ml−1, CST, D21H3), TROP2 (3.29 μg ml−1, Abcam, SP294), CK5 (0.142 μg ml−1, CST, E2T4B) and OLFM4 (0.27 μg ml−1, CST, D1E4M); 2.5 cycles of stripping for Ki-67 (1:100, Biocare, SP6). After six sequential rounds of staining, the sections were stained with Hoechst (Invitrogen, 33342) to visualize nuclei and mounted with ProLong Gold antifade reagent mounting medium (Invitrogen, P36930).

    Multispectral imaging and spectral unmixing

    Seven-colour multiplex-stained slides were imaged using the Vectra Multispectral Imaging System version 3 (Akoya). Scanning was performed at ×20 (×200 final magnification). Filter cubes used for multispectral imaging were DAPI, FITC, Cy3, Texas Red and Cy5. A spectral library containing the emitted spectral peaks of the fluorophores in this study was created using the Vectra image analysis software (Akoya). Using multispectral images from single-stained slides for each marker, the spectral library was used to separate each multispectral cube into individual components (spectral unmixing) allowing for identification of the seven marker channels of interest using Inform v.2.4 image analysis software.

    Twelve-colour imaging assay

    FFPE 4 µm tissue sections of were baked for 1 h at 62 °C in vertical slide orientation with subsequent prestaining of deparaffinization (Leica, Bond Dewax Solution, AR9222) and 35 min of Bond ER2 (Leica, AR9640) antigen retrieval at 100 °C was performed on the Leica Bond RX automated research strainer. The Lunaphore COMET imaging chip (MK03) was placed over the acquisition region based on alignment with regions selected on a haematoxylin and eosin stained image, then loaded into the COMET device and subjected to a first cycle of autofluorescence image acquisition, followed by nine cycles of staining, imaging and elution. Each cycle contained one rabbit primary antibody and/or one mouse primary antibody (HER2 (1 μg ml−1, CST, D8F12); CDX2 (0.46 μg ml−1, CST, D11D10); PROX1 (1.5 μg ml−1, CST, D2J6J); Ki-67 (1 μg ml−1, Abcam, EPR3610); vimentin (0.33 μg ml−1, Thermo Fisher Scientific, V9); PLCG2 (1 μg ml−1, CST, E5U4T); PLCG2 (1 μg ml−1, CST, E5U4T); CHGA (0.13 μg ml−1, CST, 5H7); CK5 (0.213 μg ml−1, CST, E2T4B); SYNC (2 μg ml−1, Thermo Fisher Scientific, Poly); CK20 (0.21 μg ml−1, CST, D9Z1Z); GPC1 (6.47 μg ml−1, Abcam, EPR22580-72)) detected with an Alexa Flour conjugated species-specific secondary antibody (Invitrogen, 10 µg ml−1; Supplementary Table 8). The cyclic staining, imaging and elution was automatically performed by COMET. The optimal concentration, position in the panel and incubation time (4 min for each marker per cycle, but 8 min for HER2) of each marker in the panel was optimized to be concordant with its corresponding single diaminobenzidine immunohistochemistry stain. Optimal immunohistochemistry staining for each marker was determined by an MSK pathologist (T.H.) according to the DAB staining result, as performed on the Leica BondRX Stainer using the BOND Polymer Refine Detection Kit (Leica, DS9800). All antibodies were pre-diluted for COMET analysis with Intercept Antibody Diluent (LI-COR, 927-65001). After each staining cycle, elution of primary and secondary antibodies was performed using elution buffer solution (Lunaphore, BU07-L). For each sample, a 82.5 mm2 region of interest was imaged under the Lunaphore slide cover chip at ×20 magnification, and a full channel stacked OME.tif file was generated automatically once all cycles were completed.

    Single-cell segmentation

    We used Mesmer (v.0.12)81, a deep-learning cell segmentation algorithm, to identify cell boundaries in all COMET and Vectra images. The input to Mesmer (v.0.12) is a single nucleus-stained image and a single membrane or cytoplasm-stained image to define the extent of each nucleus and cell. We used DAPI as a nuclear marker for all COMET and Vectra images. To create an image that will define the boundaries of multiple cell types, we combined the channels for several cell-type-specific membrane or cytoplasmic markers into a single image by min–max scaling each channel (using the MinMaxScaler function in the sklearn.preprocessing (v.1.4.2) package with the default parameters) and summing them. For COMET, we combined CK20, HER2, CK5, SYNC (normal and tumour epithelial cells) and VIM (stromal cells). For Vectra panel 1, we used HER2, SOX2, CK20, CDX2 and CHGA (tumour cells) and VIM (stromal cells). For Vectra panel 2, we used TP63, OLFM4, TROP2 and CK5 (tumour cells) and PLCG2 (stromal cells).

    We ran Mesmer (v.0.12) on these images with the default parameters to predict cell boundaries, and calculated the cell size, eccentricity and centroid of each cell boundary using the regionprops function (default parameters) in the Python skimage (v.0.23.2) package. When running Mesmer (v.0.12), we first subsampled COMET images by half so that they would fit in system memory (128 GB of memory). For both cell size and DAPI expression, we found the distributions of segmented cells produced by Mesmer (v.0.12) were bimodal and the lower mode contained primarily empty regions and not real cells. We therefore filtered out all predicted cell boundaries below threshold values of 30 px2 cell size (estimated from the distribution) and a log2-normalized DAPI intensity of 11 (COMET), 1 (Vectra panel 1) and 1 (Vectra panel 2) (estimated from the distribution). This resulted in a COMET dataset of 6,852,690 cells across 18 FOVs, a Vectra panel 1 dataset of 6,090,968 cells across 664 FOVs; and a Vectra panel 2 dataset of 5,213,051 cells across 602 FOVs.

    Normalization, background removal and thresholding

    Raw per-cell marker expression levels were first determined by summing the brightness values over all pixels within each cell boundary. To ensure that our downstream analysis was not influenced by cell size, we then divided the per-cell expression for each channel by the cell boundary sizes determined by the regionprops function, as described above. Once normalized, all cells were pooled into cell-by-expression matrices within the same imaging technology and panel (Vectra panel 1, Vectra panel 2 and COMET) for downstream analyses and annotated with patient- and sample-level metadata.

    CK5 background in Vectra panel 2

    To address the high levels of background in CK5 staining, an experienced physician manually annotated 167 FOVs out of 602 to denote whether they have high background signal. To identify high-background images in the remaining 435 FOVs, we first found the highest level of background CK5 signal (10th percentile of expression across all cells in the FOV) within FOVs labelled low-background (around 0.0068). We then classified all unlabelled FOVs with a background CK5 signal of >0.0068 as high background. As a result, 327 unlabelled FOVs with low background were used in later analyses, and 108 with high background were removed. In total, we used 456 FOVs with a low level of CK5 background expression in all figures involving Vectra panel 2.

    Thresholding for tumour markers in Vectra panels 1 and 2

    To call cells as ‘positive’ for the tumour markers in each panel, we calculated the quantile values of expression across all cells in small increments from 0.0 to 1.0 and found the knee-point of these values (typically between 0.8 and 0.9 for all markers). This method enabled us to avoid using a single quantile threshold for all markers, which would be unreasonable, as markers have different expression distributions across samples. The intuition behind our approach is that the knee-point at which quantile values start increasing rapidly reflects where the population changes from negative to positive. This can also be seen as a way of finding the knee-point in the distribution without fitting an estimated distribution to the data. We validated our labels by comparing the expression of tumour markers with tumour regions that were manually annotated by a physician in a subset of images. We then took all cells called as positive for a marker and repeated the knee-point analysis to identify the subset of cells with high marker expression, which we report as a percentage of all cells positive for any tumour marker, listed above in the ‘Single-cell segmentation’ section, from the same panel; we quantify CK20 in panel 1 and OLFM4, TROP2 and CK5 in panel 2 this manner (Extended Data Figs. 3f and 5a–d).

    PROX1+ and CDX2+ cell identification in COMET

    For each COMET image, regions corresponding to normal epithelium and tumour tissue were manually demarcated by an experienced physician based on histology, and we retained only cells belonging to these masked regions for downstream analyses. We included this preliminary filtering step to (1) remove most stromal cells, therefore reducing the computational cost downstream; and (2) distinguish tumour cells from normal epithelium using histological evidence, as this was not possible from marker expression alone (for example, due to expression of stromal marker genes in basal-like tumour cells). As we use only COMET data to compare CDX2+ intestinal and PROX1+ fetal-like cells, we first restricted our analysis to cells expressing either PROX1 or CDX2 above a stringent level of background (99th percentile of expression in unmasked regions calculated separately for each image). We then removed 6 samples with fewer than 1% PROX1-expressing cells, leaving 7 samples. For each of these samples, we further labelled cells as CDX2+, PROX1+ or double+ if their expression of one or both genes was >0.5 s.d. above the mean.

    Organoid experimental methods

    Organoid and cell culture

    For experiments, organoids were collected from Matrigel with 3 mM EDTA in DPBS and, where indicated, were treated with TrypLE (Thermo Fisher Scientific) for 5–10 min at 37 °C and filtered through a 40-μm cell strainer to generate single cells. Cells were plated at a density of 2,000 cells per 40 μl of Matrigel and were incubated at 37 °C for 30 min until the domes solidified. Organoids were cultured in HISC (Advanced DMEM/F12 (AdDF12; Thermo Fisher Scientific), GlutaMAX (2 mM, Thermo Fisher Scientific), HEPES (10 mM, Thermo Fisher Scientific), N-acetyl-l-cysteine (1 mM, Sigma-Aldrich), B27 supplement with vitamin A (Thermo Fisher Scientific), primocin (100 μg ml−1, InvivoGen), EGF (50 ng ml−1, Peprotech), Noggin (100 ng ml−1, Peprotech), A8301 (500 nM, Sigma-Aldrich), FGF2 (50 ng ml−1, Peprotech), IGF-I (100 ng ml−1, Peprotech)) or IGFF (HISC without EGF, Noggin, A-8301, FGF2, IGF-I) medium supplemented with Y-27632. The medium was changed every 3–4 days. Organoids were collected at 7 days for downstream assays. Where indicated, small intact organoids (2–3 days after passage) were treated with 250 nM irinotecan added to HISC medium for 7 days and then collected for downstream assays. Lentiviral production and transduction of organoids was performed as described previously82. In brief, HEK293T cells (ATCC) were cultured in DMEM supplemented with 10% FBS, GlutaMAX (2 mM, Thermo Fisher Scientific) and penicillin–streptomycin (100 IU ml−1, 0.1 mg ml−1, Thermo Fisher Scientific). All cells tested negative for mycoplasma. For scRNA-seq, organoids were collected from Matrigel with 3 mM EDTA in DPBS, dissociated to single cells with Accutase (Sigma-Aldrich) for 30–45 min at room temperature, washed with IGFF medium and processed as described above.

    Inducible knockdown

    For doxycycline inducible PROX1 knockdown experiments, de novo 97-mer mirE shRNA sequences were synthesized (IDT Ultramers) and PCR amplified using the primers miRE-Xho-fw (5′-TGAACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG-3′) and miRE-EcoOligo-rev (5′-TCTCGAATTCTAGCCCCTTGAAGTCCGAGGCAGTAGGC-3′) as described previously83. Sequences (shPROX1-1: TGCTGTTGACAGTGAGCGCGAGGACCAAGATGTCATCTCATAGTGAAGCCACAGATGTATGAGATGACATCTTGGTCCTCATGCCTACTGCCTCGGA; shPROX1-2: TGCTGTTGACAGTGAGCGCCCCCGAGAAAGTTACAGAGAATAGTGAAGCCACAGATGTATTCTCTGTAACTTTCTCGGGGATGCCTACTGCCTCGGA) were cloned into the LT3GEPIR backbone83 (Addgene, 111177) and used to generate lentiviral particles to transduce into organoids as described previously82. The original plasmid containing an shRNA sequence to Renilla 306 luciferase (shRen.713) was used as a control. Transduced organoids were selected using HISC medium supplemented with 2 μg ml−1 puromycin for 7 days. For inducible knockdown experiments, organoids were dissociated into single cells, plated at a density of 2,000 cells per 40 μl of Matrigel and maintained in HISC or IGFF medium supplemented with 2 μg ml−1 doxycycline (Thermo Fisher Scientific) unless otherwise specified for 7 days before downstream assays. For organoid initiation and outgrowth assays, organoids containing inducible PROX1 or control shRNA cultured in HISC medium supplemented with 2 μg ml−1 doxycycline for 7 days were dissociated into single cells, stained with DAPI (1 μg ml−1, Thermo Fisher Scientific), and live cell (DAPI) and GFP+ sorted to select for healthy cells expressing the shRNA construct, and plated at a density of 750 cells per 15 μl Matrigel in HISC medium without Y-27632 and supplemented with 2 μg ml−1 doxycycline, and imaged at 7 days (BioTek).

    Western blotting

    Approximately 4,000 organoids (3–4 million cells) were recovered from Matrigel using 3 mM EDTA in DPBS, washed, centrifuged (200g, 5 min, 4 °C) and lysed with 1× RIPA buffer supplemented with PPI (1:100, Sigma-Aldrich, 04693132001) and benzonase (1:100, Thermo Fisher Scientific, 70-664-3) on ice for 30 min. The protein concentration was determined using Pierce BCA assay (Thermo Fisher Scientific, 23227). A total of 10 μg protein per sample was separated by SDS–PAGE on Bis-Tris polyacrylamide gels (Thermo Fisher Scientific, NW04120BOX), transferred to activated PVDF membranes (Millipore, IPFL00010) and blocked in 3% BSA-TBST solution for 30 min. The membranes were incubated overnight at 4 °C with the following antibodies: mouse anti-β-actin (1:1,000, Thermo Fisher Scientific, AM4302) and rabbit anti-PROX1 (1:1,000, Abcam, ab199359), followed by secondary antibody incubation with 488 anti-mouse and 680 anti-rabbit secondary antibodies (1:5,000, LI-COR Biosciences, 1 h, room temperature) before imaging (Odyssey CLx). Western blots were quantified using ImageJ (v.1.53t)84.

    Organoid whole-mount immunofluorescence

    Whole organoids were plated in 10% Matrigel and HISC medium on chamber slides with removable wells (Thermo Fisher Scientific, 177380), and incubated at 37 °C for 1 h. The organoids were then fixed in 4% paraformaldehyde in PME solution for 10 min, washed twice with IF buffer (0.2% Triton X-100, 0.05% Tween-20 in DPBS), permeabilized (0.5% Triton X-100 in DPBS for 10 min, room temperature), blocked in 10% normal goat serum (Thermo Fisher Scientific, 50062Z) for 30 min before overnight primary antibody incubation with 1:500 rabbit anti-PROX1 (Abcam, ab199359) in 10% normal goat serum at 4 °C. Organoids were incubated with 1:400 of 594 anti-rabbit antibody (Invitrogen, A11012) for 1 h at room temperature, washed three times with IF buffer and one time with cold DPBS. The wells were removed and the samples mounted using medium containing DAPI (Novus Biologics, H-1200-NB). Imaging was performed on the Zeiss Axio Imager 2 with Apotome structured illumination microscope. PROX1 expression was quantified using the CellProfiler (v.4.2.5) software85.

    RT–qPCR

    Total RNA was extracted from organoids using the RNeasy Mini kit (Qiagen). Total RNA (3–4 μg) was used to prepare cDNA using the Transcriptor First-Strand cDNA synthesis kit (Roche). qPCR was performed with TaqMan gene expression assay primers (Thermo Fisher Scientific; PROX1, Hs00896293_m1; GAPDH, Hs02758991_g1; ELF5, Hs01063022_m1; KRT23, Hs00210096_m1; TFF3, Hs00902278_m1; FABP1, Hs00155026_m1; TRPS1, Hs00936363_m1; GNAI1, Hs01053355_m1; FGF20, Hs00173929_m1; NELL2, Hs00196254_m1; NRXN3, Hs01028186_m1; POMC, Hs01596743_m1; KRT20, Hs00300643_m1; GPC1, Hs00892476_m1; LGR5, Hs00173664_m1; TMEM132A, Hs01096434_m1; NEUROD1, Hs01922995_s1; CHGB, Hs01084631_m1), the Relative expression was quantified using the ΔΔCt method, normalized to the expression of GAPDH on the QuantStudio 6 and 7 Pro real-time PCR system (Applied Biosystems).

    Orthotopic xenograft experiments

    All animal experiments were performed in accordance with protocols approved by the Memorial Sloan Kettering Cancer Center Institutional Animal Care and Use Committee (IACUC). NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ, 005557) mice were obtained from the Jackson Laboratory and were transplanted at 6 weeks of age86. Mice were maintained in a specific-pathogen-free (SPF) facility under a 12 h–12 h light–dark cycle under controlled temperature and humidity, and given ad libitum access to standard diet or irradiated diet supplemented with 2,500 ppm doxycycline (Modified LabDiet 5053) and water. For orthotopic caecal and intrahepatic injections, OKG146P, OKG146Li, OKG136P or OKG136Li organoids were transduced with pLenti-PGK-Akaluc (AkaLuc) or pLenti-PGK-tdTomato-Akaluc (TdT-AkaLuc) virus (subcloned from pLenti-PGK-Venus-Akaluc(neo)) and HR180-LGR5-iCT plasmids through Gibson assembly (Addgene, 124701, 129094). For intrahepatic injections assessing PROX1 knockdown, OKG146P and OKG136P lines expressing shRNAs to PROX1 or Renilla control were transduced with pLenti-PGK-Akaluc (AkaLuc). For caecal injections, 200,000 cells from each organoid line were mixed with 50% Matrigel in 10 μl of HISC and injected into the caecal submucosa of NSG mice. For hepatic injections, 500,000 cells from each organoid line were mixed with 50% Matrigel in 10 μl of HISC and injected under the liver capsule of NSG mice. Weekly bioluminescence imaging was performed on the IVIS Spectrum Xenogen instrument (Caliper Life Sciences) and analysed using Living Image software v.2.50. Experimental group sizes were practically determined on the basis of five mice per cage, with n  ≥  5 age- and sex-matched mice per group. Animals were randomly assigned to experimental groups where relevant. Experimental end point was reached when tumour size exceeded >10% of body mass, or when animals showed any signs of respiratory distress or illness, such as hunched posture, failure to groom or greater than 10–15% weight loss. These limits were not exceeded in any of the experiments. The animals were euthanized at the humane end point, and tissues were collected for downstream assays. Where needed, tissues were fixed in 4% paraformaldehyde. Investigators were blinded to mouse group when scoring histopathological samples.

    Statistics and reproducibility

    In vitro experiments were repeated a minimum of three times independently with similar results.

    Reporting summary

    Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

    [ad_2]

    Source link

  • Ayala, G. E. et al. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin. Cancer Res. 14, 7593–7603 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Huang, D. et al. Nerve fibers in breast cancer tissues indicate aggressive tumor progression. Medicine 93, e172 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Oertel, H. Innervation and tumour growth: a preliminary report. Can. Med. Assoc. J. 18, 135–139 (1928).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Renz, B. W. et al. β2 adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. Cancer Cell 34, 863–867 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Latil, A. et al. Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int. J. Cancer 103, 306–315 (2003).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Osswald, M. et al. Brain tumour cells interconnect to a functional and resistant network. Nature 528, 93–98 (2015).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Venkatesh, H. S. et al. Neuronal activity promotes glioma growth through neuroligin-3 secretion. Cell 161, 803–816 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Venkatesh, H. S. et al. Electrical and synaptic integration of glioma into neural circuits. Nature 573, 539–545 (2019).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhao, C. M. et al. Denervation suppresses gastric tumorigenesis. Sci. Transl. Med. 6, 250ra115 (2014).

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Magnon, C. et al. Autonomic nerve development contributes to prostate cancer progression. Science 341, 1236361 (2013).

    Article 
    PubMed 

    Google Scholar
     

  • Balood, M. et al. Nociceptor neurons affect cancer immunosurveillance. Nature 611, 405–412 (2022).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Globig, A. M. et al. The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion. Nature 622, 383–392 (2023).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Gerendai, I. et al. Transneuronal labelling of nerve cells in the CNS of female rat from the mammary gland by viral tracing technique. Neuroscience 108, 103–118 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hebb, C. & Linzell, J. L. Innervation of the mammary gland. A histochemical study in the rabbit. Histochem. J. 2, 491–505 (1970).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Tavora, B. et al. Tumoural activation of TLR3–SLIT2 axis in endothelium drives metastasis. Nature 586, 299–304 (2020).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Brose, K. et al. Slit proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance. Cell 96, 795–806 (1999).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Nguyen-Ngoc, K. V. et al. ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium. Proc. Natl Acad. Sci. USA 109, E2595–E2604 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Aslakson, C. J. & Miller, F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399–1405 (1992).

    CAS 
    PubMed 

    Google Scholar
     

  • Bujak, J. K., Kosmala, D., Szopa, I. M., Majchrzak, K. & Bednarczyk, P. Inflammation, cancer and immunity-implication of TRPV1 channel. Front. Oncol. 9, 1087 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Liebig, C., Ayala, G., Wilks, J. A., Berger, D. H. & Albo, D. Perineural invasion in cancer: a review of the literature. Cancer 115, 3379–3391 (2009).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kastin, A. Handbook of Biologically Active Peptides (Academic, 2013).

  • Otsuka, M. & Konishi, S. Release of substance P-like immunoreactivity from isolated spinal cord of newborn rat. Nature 264, 83–84 (1976).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Eshete, F. & Fields, R. D. Spike frequency decoding and autonomous activation of Ca2+-calmodulin-dependent protein kinase II in dorsal root ganglion neurons. J. Neurosci. 21, 6694–6705 (2001).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Nishikawa, S. et al. Two histidine residues are essential for ribonuclease T1 activity as is the case for ribonuclease A. Biochemistry 26, 8620–8624 (1987).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Robertson, H. D., Webster, R. E. & Zinder, N. D. Purification and properties of ribonuclease III from Escherichia coli. J. Biol. Chem. 243, 82–91 (1968).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bremnes, R. M., Sirera, R. & Camps, C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 49, 1–12 (2005).

    Article 
    PubMed 

    Google Scholar
     

  • Huang, W. et al. Site-specific RNase A activity was dramatically reduced in serum from multiple types of cancer patients. PLoS ONE 9, e96490 (2014).

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • De Lamirande, G. Action of deoxyribonuclease and ribonuclease on the growth of Ehrlich ascites carcinoma in mice. Nature 192, 52–54 (1961).

    Article 
    ADS 
    PubMed 

    Google Scholar
     

  • Ledoux, L. Action of ribonuclease on two solid tumours in vivo. Nature 176, 36–37 (1955).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Lund, J. M. et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl Acad. Sci. USA 101, 5598–5603 (2004).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kawasaki, T. & Kawai, T. Toll-like receptor signaling pathways. Front. Immunol. 5, 461 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ojaniemi, M. et al. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur. J. Immunol. 33, 597–605 (2003).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ha, T. et al. TLR2 ligands induce cardioprotection against ischaemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Cardiovasc. Res. 87, 694–703 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hesketh, P. J. et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J. Clin. Oncol. 21, 4112–4119 (2003).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Rosso, M., Robles-Frias, M. J., Covenas, R., Salinas-Martin, M. V. & Munoz, M. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol. 29, 245–254 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Munoz, M. & Rosso, M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest. N. Drugs 28, 187–193 (2010).

    Article 
    CAS 

    Google Scholar
     

  • Nagakawa, O. et al. Effect of prostatic neuropeptides on invasion and migration of PC-3 prostate cancer cells. Cancer Lett. 133, 27–33 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Nizam, E. & Erin, N. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; effects independent of substance P. Biomed. Pharmacother. 108, 263–270 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Le, T. T. et al. Sensory nerves enhance triple-negative breast cancer invasion and metastasis via the axon guidance molecule PlexinB3. NPJ Breast Cancer 8, 116 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Austin, M., Elliott, L., Nicolaou, N., Grabowska, A. & Hulse, R. P. Breast cancer induced nociceptor aberrant growth and collateral sensory axonal branching. Oncotarget 8, 76606–76621 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Jurcak, N. R. et al. Axon guidance molecules promote perineural invasion and metastasis of orthotopic pancreatic tumors in mice. Gastroenterology 157, 838–850 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kamiya, A. et al. Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression. Nat. Neurosci. 22, 1289–1305 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zahalka, A. H. et al. Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science 358, 321–326 (2017).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Partecke, L. I. et al. Subdiaphragmatic vagotomy promotes tumor growth and reduces survival via TNFα in a murine pancreatic cancer model. Oncotarget 8, 22501–22512 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Renz, B. W. et al. Cholinergic signaling via muscarinic receptors directly and indirectly suppresses pancreatic tumorigenesis and cancer stemness. Cancer Discov. 8, 1458–1473 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Boilly, B., Faulkner, S., Jobling, P. & Hondermarck, H. Nerve dependence: from regeneration to cancer. Cancer Cell 31, 342–354 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Amit, M. et al. Loss of p53 drives neuron reprogramming in head and neck cancer. Nature 578, 449–454 (2020).

  • Kalinichenko, V. V., Mokyr, M. B., Graf, L. H. Jr, Cohen, R. L. & Chambers, D. A. Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a β-adrenergic receptor mechanism and decreased TNF-α gene expression. J. Immunol. 163, 2492–2499 (1999).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Mohammadpour, H. et al. β2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. J. Clin. Invest. 129, 5537–5552 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Benci, J. L. et al. Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade. Cell 178, 933–948 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cao, Y. Q. et al. Primary afferent tachykinins are required to experience moderate to intense pain. Nature 392, 390–394 (1998).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Wang, Y. et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465, 483–486 (2010).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Guy, C. T., Cardiff, R. D. & Muller, W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12, 954–961 (1992).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Maroulakou, I. G., Anver, M., Garrett, L. & Green, J. E. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl Acad. Sci. USA 91, 11236–11240 (1994).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hale, J. J. et al. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J. Med. Chem. 41, 4607–4614 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Padmanaban, V. et al. Organotypic culture assays for murine and human primary and metastatic-site tumors. Nat. Protoc. 15, 2413–2442 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Young, L., Sung, J., Stacey, G. & Masters, J. R. Detection of Mycoplasma in cell cultures. Nat. Protoc. 5, 929–934 (2010).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Foty, R. A simple hanging drop cell culture protocol for generation of 3D spheroids. J. Vis. Exp. https://doi.org/10.3791/2720 (2011).

  • Heil, F. et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303, 1526–1529 (2004).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732–738 (2001).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3, 196–200 (2002).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Jurk, M. et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3, 499 (2002).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Maira, S. M. et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol. Cancer Ther. 11, 317–328 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Davies, B. R. et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol. Cancer Ther. 11, 873–887 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Folkes, A. J. et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51, 5522–5532 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Padmanaban, V. et al. E-cadherin is required for metastasis in multiple models of breast cancer. Nature 573, 439–444 (2019).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Krause, S., Brock, A. & Ingber, D. E. Intraductal injection for localized drug delivery to the mouse mammary gland. J. Vis. Exp. https://doi.org/10.3791/50692 (2013).

  • Jancso, G., Kiraly, E., Such, G., Joo, F. & Nagy, A. Neurotoxic effect of capsaicin in mammals. Acta Physiol. Hung. 69, 295–313 (1987).

    CAS 
    PubMed 

    Google Scholar
     

  • Chi, J. et al. Three-dimensional adipose tissue imaging reveals regional variation in beige fat biogenesis and PRDM16-dependent sympathetic neurite density. Cell Metab. 27, 226–236 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Luppi, P. H., Fort, P. & Jouvet, M. Iontophoretic application of unconjugated cholera toxin B subunit (CTb) combined with immunohistochemistry of neurochemical substances: a method for transmitter identification of retrogradely labeled neurons. Brain Res. 534, 209–224 (1990).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Gee, K. R. et al. Chemical and physiological characterization of fluo-4 Ca2+-indicator dyes. Cell Calcium 27, 97–106 (2000).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

[ad_2]

Source link

  • Decoding the interplay between genetic and non-genetic drivers of metastasis

    [ad_1]

  • Gerstberger, S., Jiang, Q. & Ganesh, K. Metastasis. Cell 186, 1564–1579 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Miroshnychenko, D. et al. Spontaneous cell fusions as a mechanism of parasexual recombination in tumour cell populations. Nat. Ecol. Evol. 5, 379–391 (2021).

    Article 
    PubMed 

    Google Scholar
     

  • Gast, C. E. et al. Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci. Adv. 4, eaat7828 (2018).

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lu, X. & Kang, Y. Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants. Proc. Natl Acad. Sci. USA 106, 9385–9390 (2009).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Black, J. R. M. & McGranahan, N. Genetic and non-genetic clonal diversity in cancer evolution. Nat. Rev. Cancer https://doi.org/10.1038/s41568-021-00336-2 (2021).

  • Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-21-1059 (2022).

  • Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23–28 (1976).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Killela, P. J. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl Acad. Sci. USA 110, 6021–6026 (2013).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • PCAWG Transcriptome Core Group et al. Genomic basis for RNA alterations in cancer. Nature 578, 129–136 (2020). This genomic–transcriptomic analysis highlights the range of genomically encoded transcriptomic alterations in cancer, and the impact of somatic copy-number alterations on gene expression.

    Article 
    ADS 

    Google Scholar
     

  • ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).

    Article 
    ADS 

    Google Scholar
     

  • Martínez-Ruiz, C. et al. Genomic-transcriptomic evolution in lung cancer and metastasis. Nature 616, 543–552 (2023). This paper explores links between genomic and transcriptomic alterations during lung cancer evolution, highlighting the influence of genomic alterations on global patterns of allele-specific gene expression and RNA editing, as well as their interplay during metastasis.

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gröbner, S. N. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321–327 (2018).

    Article 
    ADS 
    PubMed 

    Google Scholar
     

  • Bonnal, S. C., López-Oreja, I. & Valcárcel, J. Roles and mechanisms of alternative splicing in cancer—implications for care. Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-020-0350-x (2020).

  • Anczuków, O. & Krainer, A. R. Splicing-factor alterations in cancers. RNA 22, 1285–1301 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 174, 1034–1035 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Patel, S. A. et al. The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer. Nature 606, 999–1006 (2022).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Househam, J. et al. Phenotypic plasticity and genetic control in colorectal cancer evolution. Nature 611, 744–753 (2022).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gazzoli, I., Loda, M., Garber, J., Syngal, S. & Kolodner, R. D. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res. 62, 3925–3928 (2002).

    CAS 
    PubMed 

    Google Scholar
     

  • Baylin, S. B. & Jones, P. A. Epigenetic determinants of cancer. Cold Spring Harb. Perspect. Biol. 8, a019505 (2016).

  • Pan, H. et al. Discovery of candidate DNA methylation cancer driver genes. Cancer Discov. 11, 2266–2281 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Fennell, K. A. et al. Non-genetic determinants of malignant clonal fitness at single-cell resolution. Nature 601, 125–131 (2022).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Quinn, J. J. et al. Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science 371, eabc1944 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yang, D. et al. Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell 185, eabc1944 (2022).

    Article 

    Google Scholar
     

  • Karras, P. et al. A cellular hierarchy in melanoma uncouples growth and metastasis. Nature https://doi.org/10.1038/s41586-022-05242-7 (2022). This study provides evidence that tumour growth and metastatic dissemination in a preclinical mouse model of melanoma can be fuelled by transcriptionally and spatially distinct melanoma subpopulations.

  • Schmitt, M. J. et al. Phenotypic mapping of pathologic cross-talk between glioblastoma and innate immune cells by synthetic genetic tracing. Cancer Discov. 11, 754–777 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Mehrabadi, F. R. et al. Profiles of expressed mutations in single cells reveal subclonal expansion patterns and therapeutic impact of intratumor heterogeneity. Preprint at bioRxiv https://doi.org/10.1101/2021.03.26.437185 (2021).

  • Schiffman, J. S. et al. Defining ancestry, heritability and plasticity of cellular phenotypes in somatic evolution. Preprint at bioRxiv https://doi.org/10.1101/2022.12.28.522128 (2022). This preprint links phylogenetic ancestry with single cellular phenotypes and explores their relative heritability in somatic evolution.

  • Brock, A., Chang, H. & Huang, S. Non-genetic heterogeneity—a mutation-independent driving force for the somatic evolution of tumours. Nat. Rev. Genet. 10, 336–342 (2009).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Quintanal-Villalonga, Á. et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat. Rev. Clin. Oncol. 17, 360–371 (2020).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Driessens, G., Beck, B., Caauwe, A., Simons, B. D. & Blanpain, C. Defining the mode of tumour growth by clonal analysis. Nature 488, 527–530 (2012).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Calabrese, C. et al. A perivascular niche for brain tumor stem cells. Cancer Cell https://doi.org/10.1016/j.ccr.2006.11.020 (2007).

  • Oskarsson, T., Batlle, E. & Massagué, J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell https://doi.org/10.1016/j.stem.2014.02.002 (2014).

  • Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47–54 (2016).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Turajlic, S. & Swanton, C. Metastasis as an evolutionary process. Science 352, 169–175 (2016).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Birkbak, N. J. & McGranahan, N. Cancer genome evolutionary trajectories in metastasis. Cancer Cell 37, 8–19 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Tomczak, K., Czerwińska, P. & Wiznerowicz, M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp. Oncol. 19, A68–A77 (2015).


    Google Scholar
     

  • Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 575, 210–216 (2019).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Robinson, D. R. et al. Integrative clinical genomics of metastatic cancer. Nature 548, 297–303 (2017).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Nguyen, B. et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185, 563–575 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Christensen, D. S. et al. Treatment represents a key driver of metastatic cancer evolution. Cancer Res. 82, 2918–2927 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hu, Z., Li, Z., Ma, Z. & Curtis, C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat. Genet. 52, 701–708 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Martínez-Jiménez, F. et al. Pan-cancer whole-genome comparison of primary and metastatic solid tumours. Nature 618, 333–341 (2023). This large, unpaired analysis of primary and metastatic tumours demonstrated that overall, primary and metastatic genomes tended to be relatively similar, without obvious ‘gatekeeper’ events that unlock metastatic potential.

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 173, 1823 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Baslan, T. et al. Ordered and deterministic cancer genome evolution after p53 loss. Nature 608, 795–802 (2022).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lengel, H. B. et al. Genomic mapping of metastatic organotropism in lung adenocarcinoma. Cancer Cell 41, 970–985 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal. Cell 173, 581–594.e12 (2018). This systematic analysis of paired primary and metastatic clear-cell renal carcinoma biopsies reveals that genomic events (in particular, 9p loss) are highly selected in metastasis.

  • Al Bakir, M. et al. The evolution of non-small cell lung cancer metastases in TRACERx. Nature 616, 534–542 (2023). This paired analysis of lung cancer primary and metastatic tumours revealed that metastatic competence is shaped by selection of genomic events occurring within the primary tumour.

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chen, F. et al. Moving pan-cancer studies from basic research toward the clinic. Nat. Cancer 2, 879–890 (2021).

    Article 
    PubMed 

    Google Scholar
     

  • Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Patton, E. E. et al. Melanoma models for the next generation of therapies. Cancer Cell https://doi.org/10.1016/j.ccell.2021.01.011 (2021).

  • Hebert, J. D., Neal, J. W. & Winslow, M. M. Dissecting metastasis using preclinical models and methods. Nat. Rev. Cancer 23, 391–407 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Vander Velde, R., Shaffer, S. & Marusyk, A. Integrating mutational and nonmutational mechanisms of acquired therapy resistance within the Darwinian paradigm. Trends Cancer 8, 456–466 (2022).

    Article 

    Google Scholar
     

  • McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613–628 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bejarano, L., Jordāo, M. J. C. & Joyce, J. A. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 11, 933–959 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wu, Y. et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discov. 12, 134–153 (2022).

    Article 
    MathSciNet 
    CAS 
    PubMed 

    Google Scholar
     

  • de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374–403 (2023).

    Article 
    PubMed 

    Google Scholar
     

  • Beck, B. & Blanpain, C. Unravelling cancer stem cell potential. Nat. Rev. Cancer https://doi.org/10.1038/nrc3597 (2013).

  • Dick, J. E. Stem cell concepts renew cancer research. Blood 112, 4793–4807 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Shackleton, M., Quintana, E., Fearon, E. R. & Morrison, S. J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell https://doi.org/10.1016/j.cell.2009.08.017 (2009).

  • Clevers, H. The cancer stem cell: Premises, promises and challenges. Nat. Med. 17, 313–319 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Lawson, D. A. et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 526, 131–135 (2015).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gkountela, S. et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell 176, 98–112 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Melo, F. D. S. E. et al. A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer. Nature https://doi.org/10.1038/nature21713 (2017).

  • Guo, W. et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148, 1015–1028 (2012).

  • De Sousa E Melo, F. et al. A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer. Nature 543, 676–680 (2017). This study demonstrated that ablation of LGR5+ CSCs does not prevent long-term tumour growth, as this compartment can be replenished by de-differentiation of LGR5 progenitors, but it does decrease metastasis incidence, which indicates that dissemination and/or colonization of distant sites may originate from LGR5+ CSCs.

  • Fumagalli, A. et al. Plasticity of Lgr5-negative cancer cells drives metastasis in colorectal cancer. Cell Stem Cell 26, 569–578 (2020). This article provides experimental evidence that CRC metastases are seeded by LGR5 cells, which have an intrinsic ability to become CSCs in a niche-independent manner and can restore epithelial hierarchies in metastatic tumours.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Nowosad, A., Marine, J.-C. & Karras, P. Perivascular niches: critical hubs in cancer evolution. Trends Cancer 9, 897–910 (2023).

    Article 
    PubMed 

    Google Scholar
     

  • Lambert, A. W. & Weinberg, R. A. Linking EMT programmes to normal and neoplastic epithelial stem cells. Nat. Rev. Cancer 21, 325–338 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Shen, Y. et al. Reduction of liver metastasis stiffness improves response to bevacizumab in metastatic colorectal cancer. Cancer Cell 37, 800–817 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wei, S. C. et al. Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway. Nat. Cell Biol. 17, 678–688 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Vaupel, P. & Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225–239 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Nieto, M. A. Epithelial plasticity: a common theme in embryonic and cancer cells. Science https://doi.org/10.1126/science.1234850 (2013).

  • Nieto, M. A., Huang, R. Y. Y. J., Jackson, R. A. A. & Thiery, J. P. P. EMT: 2016. Cell https://doi.org/10.1016/j.cell.2016.06.028 (2016).

  • Thiery, J. P., Acloque, H., Huang, R. Y. J. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871–890 (2009).

  • Yang, M.-H. et al. Direct regulation of TWIST by HIF-1α promotes metastasis. Nat. Cell Biol. 10, 295–305 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ye, X. & Weinberg, R. A. Epithelial-mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol. 25, 675–686 (2015).

  • Ocaña, O. H. et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22, 709–724 (2012).

    Article 
    PubMed 

    Google Scholar
     

  • Revenco, T. et al. Context dependency of epithelial-to-mesenchymal transition for metastasis. Cell Rep. 29, 1458–1468 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Beerling, E. et al. Plasticity between epithelial and mesenchymal states unlinks EMT from metastasis-enhancing stem cell capacity. Cell Rep. https://doi.org/10.1016/j.celrep.2016.02.034 (2016).

  • Pastushenko, I. et al. Identification of the tumour transition states occurring during EMT. Nature 556, 463–468 (2018). This study provides evidence that spontaneous EMT proceeds through intermediate transition states with different metastatic propensities, rather than through an on-and-off switch.

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525–530 (2015).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472–476 (2015).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Padmanaban, V. et al. E-cadherin is required for metastasis in multiple models of breast cancer. Nature 573, 439–444 (2019).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Graziani, V., Rodriguez-Hernandez, I., Maiques, O. & Sanz-Moreno, V. The amoeboid state as part of the epithelial-to-mesenchymal transition programme. Trends Cell Biol. https://doi.org/10.1016/j.tcb.2021.10.004 (2022).

  • Lüönd, F. et al. Distinct contributions of partial and full EMT to breast cancer malignancy. Dev. Cell 56, 3203–3221 (2021).

    Article 
    PubMed 

    Google Scholar
     

  • Simeonov, K. P. et al. Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell 39, 1150–1162 (2021). Using an elegant inducible CRISPR–Cas9-based lineage recorder with highly efficient single-cell capture of both transcriptional and phylogenetic information, this study demonstrates that the metastatic potential peaks in rare, late-hybrid EMT states, and goes on to show that the gene signatures of late-hybrid EMT states are predictive of reduced survival in both patients with pancreatic cancer and patients with lung cancer.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pastushenko, I. & Blanpain, C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 29, 212–226 (2019).

  • Ligorio, M. et al. Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer. Cell 178, 160–175 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cui, J. et al. MLL3 loss drives metastasis by promoting a hybrid epithelial–mesenchymal transition state. Nat. Cell Biol. https://doi.org/10.1038/s41556-022-01045-0 (2023).

  • Campbell, N. R. et al. Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation. Dev. Cell 56, 2808–2825 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pastushenko, I. et al. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature 589, 448–455 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Malagoli Tagliazucchi, G., Wiecek, A. J., Withnell, E. & Secrier, M. Genomic and microenvironmental heterogeneity shaping epithelial-to-mesenchymal trajectories in cancer. Nat. Commun. 14, 789 (2023).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sullivan, J. P. et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 4, 1299–1309 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Stott, S. L. et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci. Transl. Med. 2, 25ra23 (2010).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580–584 (2013).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cheung, K. J. et al. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc. Natl Acad. Sci. USA 113, E854–E863 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wirtz, D., Konstantopoulos, K. & Searson, P. C. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat. Rev. Cancer https://doi.org/10.1038/nrc3080 (2011).

  • Huang, Q. et al. Shear stress activates ATOH8 via autocrine VEGF promoting glycolysis dependent-survival of colorectal cancer cells in the circulation. J. Exp. Clin. Cancer Res. 39, 25 (2020).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wang, X. et al. Fluid shear stress promotes autophagy in hepatocellular carcinoma cells. Int. J. Biol. Sci. 14, 1277–1290 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Szczerba, B. M. et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature 566, 553–557 (2019).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Aceto, N. et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158, 1110–1122 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wrenn, E. D. et al. Regulation of collective metastasis by nanolumenal signaling. Cell 183, 395–410 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Xia, F. et al. Genome-wide in vivo screen of circulating tumor cells identifies SLIT2 as a regulator of metastasis. Sci. Adv. 8, eabo7792 (2022).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rahrmann, E. P. et al. The NALCN channel regulates metastasis and nonmalignant cell dissemination. Nat. Genet. https://doi.org/10.1038/s41588-022-01182-0 (2022).

  • Rhim, A. D. et al. Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. Gastroenterology 146, 647–651 (2014).

    Article 
    PubMed 

    Google Scholar
     

  • Hosseini, H. et al. Early dissemination seeds metastasis in breast cancer. Nature 540, 552–558 (2016).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Harper, K. L. et al. Mechanism of early dissemination and metastasis in Her2+ mammary cancer. Nature 540, 588–592 (2016).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Podsypanina, K. et al. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321, 1841–1844 (2008).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Massagué, J. & Ganesh, K. Metastasis-initiating cells and ecosystems. Cancer Discov. 11, 971–994 (2021).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • El-Kebir, M., Satas, G. & Raphael, B. J. Inferring parsimonious migration histories for metastatic cancers. Nat. Genet. 50, 718–726 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Reiter, J. G. et al. Minimal functional driver gene heterogeneity among untreated metastases. Science 361, 1033–1037 (2018).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Turajlic, S. et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx Renal. Cell 173, 595–610 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sottoriva, A. et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 47, 209–216 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Noorani, A. et al. Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma. Nat. Genet. 52, 74–83 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sanborn, J. Z. et al. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc. Natl Acad. Sci. USA 112, 10995–11000 (2015).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Maddipati, R. & Stanger, B. Z. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov. 5, 1086–1097 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Risson, E., Nobre, A. R., Maguer-Satta, V. & Aguirre-Ghiso, J. A. The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat. Cancer https://doi.org/10.1038/s43018-020-0088-5 (2020).

  • Gao, H. et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 150, 764–779 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gao, H. et al. Multi-organ site metastatic reactivation mediated by non-canonical discoidin domain receptor 1 signaling. Cell 166, 47–62 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cock, J. M. D. et al. Inflammation triggers Zeb1-dependent escape from tumor latency. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-16-0608 (2016).

  • Albrengues, J. et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361, eaao4227 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Correia, A. L. et al. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature 594, 566–571 (2021).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Fane, M. E. et al. Stromal changes in the aged lung induce an emergence from melanoma dormancy. Nature 606, 396–405 (2022).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Jin, X. et al. A metastasis map of human cancer cell lines. Nature 588, 331–336 (2020).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Frankell, A. M. et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature 616, 525–533 (2023).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Duda, D. G. et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl Acad. Sci. USA 107, 21677–21682 (2010).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Peinado, H. et al. Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer https://doi.org/10.1038/nrc.2017.6 (2017).

  • Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820–827 (2005).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Psaila, B. & Lyden, D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer https://doi.org/10.1038/nrc2621 (2009).

  • Tominaga, N. et al. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat. Commun. 6, 6716 (2015).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Zhou, W. et al. Cancer-Secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25, 501–515 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Parida, P. K. et al. Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness. Cell Metab. 34, 90–105 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lee, J. W. et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature 567, 249–252 (2019).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • García-Silva, S. et al. Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism. Nat. Cancer 2, 1387–1405 (2021).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Morrissey, S. M. et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 33, 2040–2058 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hoshino, A. et al. Tumour exosome integrins determine organotropic metastasis. Nature 527, 329–335 (2015).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhang, L. et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527, 100–104 (2015).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20, 26–41 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sevenich, L. et al. Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat. Cell Biol. 16, 876–888 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rodrigues, G. et al. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat. Cell Biol. 21, 1403–1412 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Burr, M. L. et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36, 385–401.e8 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479–485 (2019).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Łuksza, M. et al. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature 606, 389–395 (2022).

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tauriello, D. V. F. et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538–543 (2018).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Huergo-Zapico, L. et al. NK-cell editing mediates epithelial-to-mesenchymal transition via phenotypic and proteomic changes in melanoma cell lines. Cancer Res. 78, 3913–3925 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Malladi, S. et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165, 45–60 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lo, H. C. et al. Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis. Nat. Cancer 1, 709–722 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Reticker-Flynn, N. E. et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell 185, 1924–1942 (2022). This study indicates that lymph node colonization induces tumour-specific immune tolerance and thereby facilitates further spreading of the disease to distant organs.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bergers, G. & Fendt, S. M. The metabolism of cancer cells during metastasis. Nat. Rev. Cancer https://doi.org/10.1038/s41568-020-00320-2 (2021).

  • Falletta, P. et al. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. Genes Dev. 31, 18–33 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • García-Jiménez, C. & Goding, C. R. Starvation and pseudo-starvation as drivers of cancer metastasis through translation reprogramming. Cell Metab. 29, 254–267 (2019).

  • Andrzejewski, S. et al. PGC-1α promotes breast cancer metastasis and confers bioenergetic flexibility against metabolic drugs. Cell Metab. 26, 778–787 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Lebleu, V. S. et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16, 992–1003 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Broadfield, L. A., Pane, A. A., Talebi, A., Swinnen, J. V. & Fendt, S. M. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev. Cell https://doi.org/10.1016/j.devcel.2021.04.013 (2021).

  • Pascual, G. et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 541, 41–45 (2017).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Nieman, K. M. et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498–1503 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ferraro, G. B. et al. Fatty acid synthesis is required for breast cancer brain metastasis. Nat. Cancer 2, 414–428 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rossi, M. et al. PHGDH heterogeneity potentiates cancer cell dissemination and metastasis. Nature 605, 747–753 (2022).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cheung, E. C. et al. Dynamic ROS control by TIGAR regulates the initiation and progression of pancreatic cancer. Cancer Cell 37, 168–182 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Crist, S. B. et al. Unchecked oxidative stress in skeletal muscle prevents outgrowth of disseminated tumour cells. Nat. Cell Biol. 24, 538–553 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Piskounova, E. et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527, 186–191 (2015).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tasdogan, A. et al. Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature 577, 115–120 (2020).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Fischer, G. M. et al. Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov. 9, 628–645 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Basnet, H. et al. Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization. eLife 8, e43627 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Davis, R. T. et al. Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing. Nat. Cell Biol. 22, 310–320 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Elia, I. et al. Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat. Commun. 8, 15267 (2017).

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Delaunay, S. et al. Mitochondrial RNA modifications shape metabolic plasticity in metastasis. Nature 607, 593–603 (2022).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Altea-Manzano, P. et al. A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling. Nat. Cancer https://doi.org/10.1038/s43018-023-00513-2 (2023).

  • Sivanand, S. et al. Cancer tissue of origin constrains the growth and metabolism of metastases. Preprint at bioRxiv https://doi.org/10.1101/2022.08.17.504141 (2022).

  • Ubellacker, J. M. et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature 585, 113–118 (2020).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Elia, I. & Haigis, M. C. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat. Metab. 3, 21–32 (2021).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Falletta, P., Goding, C. R. & Vivas-García, Y. Connecting metabolic rewiring with phenotype switching in melanoma. Front. Cell Dev. Biol. 10, 930250 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Loo, S. Y. et al. Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer. Sci. Adv. 7, eabh2443 (2021).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Romero, R. et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat. Med. 23, 1362–1368 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299–309 (2019).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Marine, J.-C., Dawson, S.-J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20, 743–756 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Diamantopoulou, Z. et al. The metastatic spread of breast cancer accelerates during sleep. Nature 607, 156–162 (2022). This study provides evidence that metastatic spreading in breast cancer follows circadian rhythmicity, with the highest levels observed during the rest phase.

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Sepich-Poore, G. D. et al. The microbiome and human cancer. Science https://doi.org/10.1126/science.abc4552 (2021).

  • Dohlman, A. B. et al. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell 185, 3807–3822 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Parhi, L. et al. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat. Commun. 11, 3259 (2020).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bullman, S. et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358, 1443–1448 (2017).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bertocchi, A. et al. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell 39, 708–724 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Fu, A. et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell 185, 1356–1372 (2022). This study reveals that tumour-resident bacteria promote the release and survival of CTCs.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Galeano Niño, J. L. et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature https://doi.org/10.1038/s41586-022-05435-0 (2022).

  • Narunsky-Haziza, L. et al. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell 185, 3789–3806 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Biswas, A. K. & Acharyya, S. Understanding cachexia in the context of metastatic progression. Nat. Rev. Cancer 20, 274–284 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wellenstein, M. D. & de Visser, K. E. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 48, 399–416 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kay, J., Thadhani, E., Samson, L. & Engelward, B. Inflammation-induced DNA damage, mutations and cancer. DNA Repair 83, 102673 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Beaver, J. A., Kluetz, P. G. & Pazdur, R. Metastasis-free survival—a new end point in prostate cancer trials. N. Engl. J. Med. 378, 2458–2460 (2018).

    Article 
    PubMed 

    Google Scholar
     

  • US National Library of Medicine. The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study. ClinicalTrials.gov clinicaltrials.gov/ct2/show/NCT03004755 (2023).

  • Bailey, C. et al. Tracking cancer evolution through the disease course. Cancer Discov. 11, 916–932 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lengrand, J. et al. Pharmacological targeting of netrin-1 inhibits EMT in cancer. Nature 620, 402–408 (2023). This article describes a clinically compatible approach to target EMT cells and thereby inhibit early metastatic dissemination.

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cassier, P. A. et al. Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer. Nature 620, 409–416 (2023).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Dhara, S. et al. Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. Nat. Commun. 12, 3044 (2021).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Denny, S. K. et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility. Cell 166, 328–342 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhao, Y. et al. EZH 2 cooperates with gain‐of‐function p53 mutants to promote cancer growth and metastasis. EMBO J. 38, e99599 (2019).

  • Cheng, Y. et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct. Target. Ther. 4, 62 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lomakin, A. et al. Spatial genomics maps the structure, nature and evolution of cancer clones. Nature https://doi.org/10.1038/s41586-022-05425-2 (2022).

  • Biermann, J. et al. Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Cell 185, 2591–2608 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Jee, J. et al. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat. Med. https://doi.org/10.1038/s41591-022-02047-z (2022).

  • Nanou, A. et al. Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival. Br. J. Cancer 122, 801–811 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446–451 (2017).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Melo, S. A. et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523, 177–182 (2015).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Albrecht, L. J. et al. Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype. Clin. Transl. Med. 12, e1090 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Martin-Perez, M., Urdiroz-Urricelqui, U., Bigas, C. & Benitah, S. A. The role of lipids in cancer progression and metastasis. Cell Metab. 34, 1675–1699 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Glinos, D. A. et al. Transcriptome variation in human tissues revealed by long-read sequencing. Nature 608, 353–359 (2022).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gong, J. et al. PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types. Nucleic Acids Res. 46, D971–D976 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576–582 (2021).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Shaffer, S. M. et al. Memory sequencing reveals heritable single-cell gene expression programs associated with distinct cellular behaviors. Cell 182, 947–959 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • [ad_2]

    Source link

  • Liver cells effectively serve as immune checkpoint regulating anti-cancer immunity

    Liver cells effectively serve as immune checkpoint regulating anti-cancer immunity

    [ad_1]

    Liver inflammation, a common side-effect of cancers elsewhere in the body, has long been associated with worse cancer outcomes and more recently associated with poor response to immunotherapy. Now, a team led by researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania has found a big reason why.

    In their study, published today in Nature Immunology, the researchers discovered that cancer-induced liver inflammation causes liver cells to secrete proteins called serum amyloid A (SAA) proteins, which circulate through the body and hinder the ability of T cells-;major anticancer weapons of the immune system-;to infiltrate and attack tumors elsewhere.

    We want to better understand what causes cancer to resist or respond to immunotherapy to help design more effective strategies for patients. Our findings show that liver cells-;with their release of SAA proteins-;effectively serve as an immune checkpoint regulating anti-cancer immunity, making them a promising therapeutic target.”


    Gregory Beatty, MD, PhD, senior author, associate professor of Hematology-Oncology and the director of Clinical and Translational Research for the Penn Pancreatic Cancer Research Center

    The study builds on previous research from the team, including co-lead authors Meredith Stone, PhD, a research associate, and Jesse Lee, a graduate student, into liver inflammation in cancer: In a 2019 study, they showed how it promotes pancreatic tumor metastasis to that organ. In 2021, researchers from the Beatty Laboratory observed that systemic inflammation, involving many of the same molecules implicated in liver metastasis, is associated with worse responses to immunotherapies in pancreatic cancer patients. The latest study was designed to investigate in more detail how liver inflammation may block the effects of these immune-boosting therapies.

    First, they looked at mouse models of pancreatic cancer, measuring the amount of T-cell infiltration in pancreatic tumors-;a basic indicator of anti-tumor immune activity. They found that mice with less T cell infiltration in their tumors tended to have more liver inflammation. These mice also showed stronger signs of an inflammatory signaling pathway called the IL-6/JAK/STAT3 pathway-;the same one the team had implicated in liver metastasis in their 2019 study.

    The researchers next showed that STAT3 activation in liver cells is associated with the reduced production of immune cells called dendritic cells, which are critical for normal T cell responses. When the scientists deleted STAT3 from liver cells, dendritic cell production and T cell activity picked up, and tumors that previously had only low T cell-infiltration developed high T cell-infiltration.

    Ultimately the team found that STAT3 activation in liver cells has its dendritic cell- and T cell-suppressing effect by inducing the production of SAA proteins, which target receptors on immune cells. Deleting the SAA proteins had the same immune-restoring effect as deleting STAT3, and increased survival times and the likelihood of cures in mice that had pancreatic tumors surgically removed.

    To get a sense whether the mouse model findings would translate to humans, the researchers measured SAA levels in tissue samples from patients whose pancreatic tumors had been surgically removed and found that those with low SAA levels at surgery went on to have significantly longer survival times afterward.

    “The translational findings in human patients highlight the likely clinical relevance of our discoveries in the mice,” Beatty said. “Now that we’ve shown how liver inflammation puts up a roadblock to immunotherapy, our next step is to see if the same pathway can be targeted to reverse inflammation in patients who already have liver metastasis.”

    The research team is now working to set up further preclinical and eventually clinical studies of STAT3- and/or SAA-inhibiting agents as potential add-on therapies in combination with immunotherapy-;for example, prior to surgery-;that could improve cancer patient outcomes.

    Support for the research was provided by the National Institutes of Health (T32 CA009140, T32-HL007439-41, K12-CA076931-21, R01-CA197916, R01CA245323, U01 CA224193 and U01 CA224175), the Damon Runyon Cancer Research Foundation, the PacMen Consortium, the US Department of Defense (W81XWH2110622, W81XWH2110621), Stand Up to Cancer, the Robert L. Fine Cancer Research Foundation, the Penn-Wistar SPORE in Skin Cancer, AACR-The Mark Foundation for Cancer Research, and the Pancreatic Cancer Action Network.

    Source:

    Journal reference:

    Stone, M. L., et al. (2024). Hepatocytes coordinate immune evasion in cancer via release of serum amyloid A proteins. Nature Immunology. doi.org/10.1038/s41590-024-01820-1.

    [ad_2]

    Source link

  • New research pinpoints key pathways in prostate cancer’s vulnerability to ferroptosis

    New research pinpoints key pathways in prostate cancer’s vulnerability to ferroptosis

    [ad_1]

    In a recent review published in the journal Nature Reviews Urology, researchers examined the molecular mechanisms and metabolic processes that drive ferroptosis — a form of cell death that plays a significant role in prostate cancer. They also connected pathways involved in ferroptosis to the metabolic reprogramming that occurs in prostate cancer cells to highlight potential avenues of targeted therapeutic interventions.

    Perspective: Unlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers. Image Credit: MattL_Images / Shutterstock

    Perspective: Unlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers. Image Credit: MattL_Images / Shutterstock

    Background

    Although the five-year survival rate in cases of localized prostate cancer is very promising (greater than 99%), metastasis or the prostate cancer progressing to the castration-resistant form of prostate cancer reduces the five-year survival rate to between 30% and 40%. Furthermore, while treatment options such as radiotherapy, chemotherapy, immunotherapy, and second-generation androgen receptor-signaling inhibitors can be used to treat advanced prostate cancer, these therapies only increase the survival rate by two to three years. Understanding the underlying mechanisms of prostate cancer can help improve and initiate early treatment.

    Recent research has found that a pathway of regulated cell death, called ferroptosis, plays a significant role in the development of prostate cancer. Ferroptosis differs from the other forms of cell death, such as autophagy, apoptosis, and necrosis, in that it is iron-dependent and is driven by lipid peroxide build-up. Studies have found that the suppression of ferroptosis is linked to tumor pathogenesis, especially in prostate cancer.

    Ferroptosis

    Ferroptosis does not have the typical characteristics of apoptosis, such as the condensation of chromatin, apoptotic body formation, and cytoskeletal breakdown. Neither does it show the hallmarks of necrosis and autophagy, such as the swelling of organelles and the formation of the autophagosomes, respectively.

    During ferroptosis, the mitochondrial size and cristae of the cells reduce, and the membrane density increases. Additionally, the polyunsaturated fatty acids that are part of the phospholipid membrane form peroxides. The lipid peroxidation could be initiated due to oxidation from iron overload, the mitochondria, or the production of reactive oxygen species due to iron. The lipid peroxidation process results in widespread damage and oxidative injury, leading to cell death.

    Cells contain various intrinsic systems to circumvent lipid peroxidation and ferroptosis. The classical method involves the use of glutathione and glutathione peroxidase 4 to decrease the levels of lipid hydroperoxides, preserving the integrity of the phospholipid bilayer and preventing ferroptosis. Inhibition of ferroptosis can also occur through ferroptosis suppressor protein 1 or dihydroorotate dehydrogenase.

    Ferroptosis and cancer

    Given the association between ferroptosis and polyunsaturated fatty acids, cancer cells, which undergo substantial metabolic reprogramming and produce reactive oxygen species, are especially susceptible to ferroptosis. Cells in malignant tumors have higher energy and iron demands, which increases their susceptibility to ferroptosis. Prostate cancer cells depend on lipid metabolism for their high energy requirements, which causes the fatty acid metabolism in prostate cancer cells to be dysregulated.

    Furthermore, factors such as lipid metabolism gene upregulation, rewiring of the oxidative phosphorylation metabolism, and increased tricarboxylic acid flux have been observed in both early and late-stage prostate cancer cells. These processes could increase the intracellular reactive oxygen species burden, promote lipid peroxidation, and cause perturbations in iron homeostasis.

    The review discussed various mechanisms through which the susceptibility of cancer cells to ferroptosis could be exploited as potential treatment avenues for advanced cancers. Targeting the defense mechanisms that inhibit ferroptosis is a promising approach. Studies have suggested that targeting the glutathione peroxidase 4 inhibition mechanism could induce ferroptosis in cancer cells that do not respond to other treatment options.

    Research also indicated that dihydroorotate dehydrogenase was not the primary ferroptosis inhibitor in cancer cells, and therefore, targeting dihydroorotate dehydrogenase might not be as effective as deletion of ferroptosis suppressor protein 1.

    Furthermore, these studies highlighted the need to thoroughly understand the pitfalls and benefits of the various mechanisms to induce ferroptosis. Knockout studies in murine models revealed that glutathione peroxidase 4 was essential in various other processes and required for survival, while knocking out ferroptosis suppressor protein 1 resulted in no developmental changes, suggesting the latter to be a preferable method to induce ferroptosis.

    This comprehensive review provided a detailed discussion of the various metabolic processes that could be exploited to make cancer cells vulnerable to ferroptosis. These methods included modulating the balance between mono- and polyunsaturated fatty acids, de-novo lipogenesis, de-novo synthesis of polyunsaturated fatty acids, and β oxidation. The researchers also expanded on the role of iron, cystine, glutamate, and glutathione metabolism in ferroptosis.

    Conclusions

    To summarize, the review provided an in-depth view of the regulated cell death process of ferroptosis, the factors that make cancer cells susceptible to ferroptosis, and its importance in prostate cancer therapy. They discussed the pathways through which ferroptosis is suppressed in cancer cells and the metabolic mechanisms that must be targeted to induce ferroptosis in prostate cancer cells selectively.

    Journal reference:

    • Anh, H., Dominic, A., Lujan, F. E., Senthilkumar, S., Bhattacharya, P. K., Frigo, D. E., & Subramani, E. (2024). Unlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers. Nature Reviews Urology. DOI: 10.1038/s41585024008699, https://www.nature.com/articles/s41585-024-00869-9

    [ad_2]

    Source link

  • Soft tumor environments prime cancer cells for survival during metastasis

    Soft tumor environments prime cancer cells for survival during metastasis

    [ad_1]

    Researchers have discovered how the mechanical properties of tumors can prime cancer cells to better survive their spread to other organs.

    A metabolic ‘survival switch’ controlled by the stiffness of triple-negative breast tumors can significantly influence how successfully their cancerous cells spread to other organs, according to new findings from the Garvan Institute of Medical Research.

    The study in cell and mouse models showed that softer tumor environments, typical of early-stage cancer, can prime triple-negative breast cancer cells to use an extra energy source for survival during metastasis. The research suggests that drugs targeting this altered cancer cell metabolism could boost treatments for metastatic triple-negative breast cancer.

    “Our research suggests triple-negative breast cancer cells in soft tissue environments are ‘primed’ to better survive the spread to other organs and that they switch on an alternative form of metabolism to do so,” says Associate Professor Cox, Head of the Matrix & Metastasis Lab at Garvan and senior author of the study published in Advanced Science.

    “This suggests that triple-negative breast cancer cells spreading from softer tumors are more aggressive, and drugs that target cancer cell metabolism may benefit patients with metastatic triple-negative breast cancer treatment.”

    A metabolic survival advantage

    Triple-negative breast cancers are highly aggressive and difficult to treat as they lack three receptors (for estrogen, progesterone and the HER2 protein) that can be targeted in other breast cancers. New treatment options are urgently needed for the 2,500 women diagnosed every year in Australia alone.

    Using biomaterials that mimic the properties of tumors, the team investigated how triple-negative breast cancer cells respond to the physical stiffness of their environment. The researchers found the cancer cells were primed to be more resilient when grown in soft environments and, when injected into mouse models, up to 11.8 times more likely to metastasize to new sites compared to those from rigid tumor environments.

    The team also discovered that soft environments altered the cancer cells’ preference for ‘fuel’ in a way that enhanced their durability while traveling through the body. These primed cells metabolized glucose – the preferred energy source for cancer cells – but they also stockpiled lipids as internal fuel reserves and in turn ramp up lipid metabolism – a more resilient energy pathway for their journey from a primary tumor site.

    “This switch to using both glucose and fats as an energy source equips cells to better survive the mechanical stresses of travelling through the blood stream and seeding new tumor sites throughout the body,” says first author Dr Elysse Filipe, who completed the study as a postdoctoral researcher at Garvan. “By blocking lipid metabolism in triple-negative breast cancer cells, we were able to ‘starve’ their high energy demand and reduce metastasis in a cell model.”

    A new approach for triple-negative breast cancer

    Our findings highlight that the physical properties of triple-negative breast cancers, which vary dynamically as the cancer progresses, profoundly impact the cancer’s ability to spread. These findings reveal a vulnerability of triple-negative breast cancers – the metastasizing cells’ reliance on diverse fuel sources to meet their high energy demands.”


    Dr. Elysse Filipe, first author 

    Associate Professor Cox adds: “The study underscores the importance of considering the mechanical diversity within and between tumors when designing new treatments for aggressive cancers. We now plan to explore whether pairing targeted metabolic inhibitors with existing therapies could limit metastasis and improve outcomes for triple-negative breast cancer patients.”

    Source:

    Journal reference:

    Filipe, E. C., et al. (2024) Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism. Advanced Science. doi.org/10.1002/advs.202307963.

    [ad_2]

    Source link

  • New microfluidic device improves the separation of tumor cells and clusters from malignant effusions

    New microfluidic device improves the separation of tumor cells and clusters from malignant effusions

    [ad_1]

    Researchers have unveiled a microfluidic device that significantly improves the separation of tumor cells and clusters from malignant effusions. This novel technology promises to advance the diagnosis and treatment monitoring of cancer by enabling the high-throughput, continuous-flow ternary separation of single tumor cells, tumor cell clusters, and white blood cells (WBCs) from clinical pleural or abdominal effusions.

    Understanding the nature of malignant effusions, teeming with tumor cells and clusters, is critical in comprehending the breadth of cancer’s impact. The significant role of tumor clusters, with their heightened potential for metastasis compared to individual cells, cannot be overstated in the context of comprehensive cancer care. While traditional techniques have shown adeptness in isolating single tumor cells, they often fall short when it comes to tumor clusters, thus limiting the scope of clinical research. The evolution of microfluidic technologies has introduced high-throughput, label-free approaches for the separation of these cells, leveraging their physical characteristics for more precise analyses. However, the challenges presented by tumor cell clusters-;primarily their rarity and fragility-;call for innovative solutions to ensure their efficient yet careful separation, maintaining their viability for downstream applications.

    In response to this challenge, a team of researchers from Southeast University has unveiled a microfluidic device, designed to achieve the precise separation of tumor entities with unprecedented efficiency. These findings were detailed in an article (DOI: 10.1038/s41378-024-00661-0) published on March 12, 2024, in Microsystems & Nanoengineering. This research introduces a device that skillfully integrates slanted spiral channels with periodic contraction-expansion arrays.

    This design utilizes inertial forces to adeptly separate single tumor cells, tumor cell clusters, and WBCs from clinical samples of pleural or abdominal effusions-;key indicators of cancer metastasis. Operating at a brisk flow rate of 3500 µL/min, the device not only manages large volumes efficiently but also ensures an exceptionally high degree of separation accuracy. With over 94% of WBCs effectively removed, the recovery of more than 97% of tumor cells and the preservation of over 90% of vital tumor cell clusters, this technology heralds a new era in cancer diagnostics, facilitating early detection, prognosis evaluation, and the monitoring of treatment outcomes.

    Our device represents a substantial advancement in the analysis of malignant effusions. By efficiently isolating tumor cell clusters, known for their considerable metastatic potential, we’re forging new pathways for the early detection and treatment of cancer.”


    Professor Nan Xiang, the study’s lead author

    This innovation marks a significant milestone in the realm of cancer diagnostics, enhancing the efficiency and throughput of tumor cell and cluster separation from malignant effusions. As such, it sets the stage for more nuanced cancer detection, ongoing monitoring, and the personalization of treatment strategies, heralding a promising future for cancer care.

    Source:

    Journal reference:

    Zhu, Z., et al. (2024). High-throughput and simultaneous inertial separation of tumor cells and clusters from malignant effusions using spiral-contraction-expansion channels. Microsystems & Nanoengineering. doi.org/10.1038/s41378-024-00661-0.

    [ad_2]

    Source link

  • Deciphering cancer plasticity:Insights from MSK research

    Deciphering cancer plasticity:Insights from MSK research

    [ad_1]

    About 90% of deaths from cancer are a result of metastasis -; that is, from cancer’s ability to spread from an initial primary tumor to seed new tumors throughout the body, often in the lungs, liver, and brain.

    And metastasis relies on cancer cells’ ability to adapt to different tissue environments throughout the body by gaining improper access to a variety of playbooks stored in our genetic code -; including gene programs that are generally available only during early stages of human development.

    Today, researchers at Memorial Sloan Kettering Cancer Center (MSK) are using innovative approaches like single-cell sequencing technology and sophisticated computational tools to illuminate cancer cells’ ability to take on new traits. And they’re applying those findings toward treating or preventing metastasis.

    In a plenary presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, Dana Pe’er, PhD, Chair of the Computational and Systems Biology Program at MSK’s Sloan Kettering Institute, highlighted three recent research collaborations between her lab and other labs at MSK that have shed new light on the ability of cancer cells to adapt and spread.

    “It’s not genetic mutations that are critical here, but the ability to access gene programs that normally are associated with other cell types -; including early developmental and embryonic programs that should not be accessed by adult cells,” Dr. Pe’er said in a recent interview. “We call this ability for cells to run new programs ‘plasticity.’ So cancer doesn’t reinvent the wheel; it exploits gene programs that exist for other biological purposes.”

    In general, she notes, plasticity isn’t a bad thing. It’s important for early development and for regeneration after injury. And the body also has built-in barriers to limit the scope of plasticity so that cells can’t just run amok.

    But in cancer, these cells can wreak havoc because they’ve lost these natural barriers.”


    Dr. Dana Pe’er, Howard Hughes Medical Institute Investigator

    Plasticity in colorectal cancer

    In the first study Dr. Pe’er presented at AACR, she teamed up with MSK physician-scientist Karuna Ganesh, MD, PhD, to look at the differences in gene programs active in the primary tumors and metastatic tumors of patients with advanced colorectal cancer. Samples of both types of tumors were collected at the same time from 31 patients -; the largest cohort of its kind -; some of whom had undergone chemotherapy and some of whom had not.

    They also created organoids from the patients’ cells -; three-dimensional clusters of cells that act more like human tissue than traditional laboratory cell cultures.

    The study found that primary tumor cells largely run programs still associated with intestinal cells, while metastases often shed their heritage as intestinal cells and take on the characteristics of squamous cells or of neuroendocrine cells, which helps them invade and survive in new tissue contexts and makes them more resistant to treatment. The team also found that chemotherapy exacerbates these transformations. The findings were published as a preprint on bioRxiv in August 2023.

    “The metastatic organoids were very different from the primary tumor organoids,” Dr. Pe’er says. “And it matters what environment they’re in, too. If you put the metastatic organoids into the liver of a mouse, they will adapt their identity in ways that primary tumor organoids are not able to -; so they’re a lot more plastic.”

    The team additionally found that a gene known as PROX1 restricted the ability of cells from the primary tumor to stray too far from their lineage as intestinal cells. But when this factor is removed, the cells gain access to many more types of cell lineages -; which scientists call noncanonical. (For reasons that aren’t fully understood, metastatic cells that lose the restrictions imposed by Prox1 are already primed to go in these noncanonical directions.)

    “I call it a mix-and-match buffet,” Dr. Peer says. “Metastatic cells have this awesome power to combine gene programs across many different types of cells, endowing them with new abilities that allow them to adapt themselves to take advantage of different conditions and environments throughout the body.”

    Plasticity in pancreatic cancer

    The second study Dr. Pe’er presented looked at about a dozen metastases collected from a single patient with pancreatic cancer, who donated their body for research under MSK’s Last Wish Program. A collaboration with physician-scientist Christine Iacobuzio-Donahue, MD, PhD, Director of the David M. Rubenstein Center for Pancreatic Cancer Research at MSK, the research used advanced single-cell and computational approaches to look at the differences in active gene programs in genetically identical cancer cells -; called clones -; that had spread to different locations in the body. The findings of the study have not yet been published.

    “What we see is that these clones are able to adapt to the pressures and metabolic demands of very different environments,” Dr. Pe’er says. “And we see that they’re able to access different gene programs that allow them to thrive in different places, different organs.”

    Moreover, even genetically different cancer cells tend to adapt to specific situations by accessing the same gene programs.

    “The big question of a cancer cell is, ‘Are you plastic or not?’ And once you are, you can acquire all these different traits. The environment is what really determines what traits will be most advantageous,” she says.

    For example, the research showed that cells that metastasize to the peritoneum -; the tissue that lines the abdominal cavity -; are able to adapt their metabolism to take advantage of the lipid-rich environment and exploit it as an energy source, she notes.

    Moving plasticity research from the lab to the clinic

    Lastly, Dr. Pe’er highlighted a third collaboration -; this time with neuro-oncologist Adrienne Boire, MD, PhD, a member of MSK’s Human Oncology and Pathogenesis Program -; which showed how plasticity can be turned against cancer cells.

    The research led to a clinical trial for patients with leptomeningeal metastasis, which is when cancer has spread to the fluid and tissues of the spinal cord and brain. The team showed that cancer cells were able to survive in this challenging environment by reprogramming themselves to outcompete other cells for iron; this fuels their growth while also preventing immune defenders in the area from getting enough iron.

    “It’s an elegant solution on the part of the cancer cell,” Dr. Boire says. “It’s really unique biology that allows them to win the competition.”

    Based on that discovery, doctors at MSK are now determining whether a drug called deferoxamine could be an effective treatment for leptomeningeal metastases by helping to remove iron from the cerebrospinal fluid.

    “The plasticity of these cells allowed several patients with several different cancers to overexpress the same two genes that are typically only expressed in myeloid cells,” Dr. Pe’er says. “And the cells not only got aberrant access to these gene programs, but they also expressed the genes at 100 times the levels seen in their normal counterparts.”

    By injecting the study drug into the spinal fluid, the idea is to prevent the cancer cells from getting the iron they need to thrive. And so far, Dr. Pe’er told the audience, initial results from the trial have been extremely promising.

    Only at a place like MSK

    “The ultimate goal, though we’re not there yet, would be to be able to target plasticity directly -; to restore some of the biological barriers or inhibit plasticity with drugs,” Dr. Pe’er says.

    And MSK is uniquely poised to pursue that aim, with strong collaborations between laboratory and clinical research; a high volume of patients that provides a wide variety of clinical samples from a wide variety of cancers, including rare ones; access to state-of-the art sequencing tools combined with some of the world’s top computational expertise; and a significant number of physician-scientists who focus both on caring for patients and finding new ways to treat their disease.

    “Not every cancer center would see enough patients with leptomeningeal metastasis to set up a clinical trial like this,” Dr. Pe’er notes. “Or have someone like Dr. Boire, who not only cares for patients with metastasis to the central nervous system but who also runs a lab dedicated to studying the underlying molecular mechanisms.”

    [ad_2]

    Source link

  • Bio-Rad launches validated antibodies for rare cell and circulating tumor cell enumeration

    Bio-Rad launches validated antibodies for rare cell and circulating tumor cell enumeration

    [ad_1]

    Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumor heterogeneity and disease progression at various stages. 

    Bio-Rad’s Genesis Cell Isolation System is a customizable benchtop solution that uses unbiased size-based cell selection to gently and efficiently capture a wide range of CTCs and other rare cells from liquid biopsy samples. After capture, the enriched cells can be recovered for downstream analysis, or immuno-stained on-slide for immunofluorescence applications such as enumeration and identification of various CTC types. 

    The enumeration of captured CTCs provides valuable insights into the surface markers that indicate cancer type and progression and is critical to understanding the mechanisms of cancer metastasis. For successful enumeration, the antibody reagents require careful selection to ensure not only sensitivity and specificity to the target cell surface marker, but also compatibility with the staining method. Bio-Rad’s new range of validated primary and secondary antibodies enables accurate immunostaining of captured CTCs, supporting cancer researchers working in this field. 

    CTC analysis is a promising tool for the study of tumor heterogeneity and disease progression, offering real-time data and unique insights into cancer metastasis,” said Stephen Kulisch, Vice President of Marketing for Bio-Rad’s Digital Biology Group. “The introduction of validated antibodies for target cell identification reflects Bio-Rad’s growing single-cell oncology product portfolio and is a testament to our commitment to deliver highly efficient rare cell capture, enrichment, enumeration, and recovery for cancer researchers.”  

    To learn more about the new validated antibodies, visit bio-rad-antibodies.com/val-abs

    BIO-RAD and CELSELECT SLIDES are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.  

    [ad_2]

    Source link

  • Study uncovers how APOBEC enzymes drive cancer mutations

    Study uncovers how APOBEC enzymes drive cancer mutations

    [ad_1]

    A research team led by the University of California, Irvine has discovered the key role that the APOBEC3A and APOBEC3B enzymes play in driving cancer mutations by modifying the DNA in tumor genomes, offering potential new targets for intervention strategies.

    The study, published today online in the journal Nature Communications, describes how the researchers identified the process by which APOBEC3A and APOBEC3B detect specific DNA structures, resulting in mutations at distinct positions within the tumor genome.

    It’s critical to understand how cancer cells accumulate mutations leading to hot spots that contribute to disease progression, drug resistance and metastasis. Both APOBEC3A and APOBEC3B were known to generate mutations in many kinds of tumors, but until now we did not know how to identify the specific type caused by each. This finding will allow us to develop novel therapies to suppress mutation formation by directly targeting each enzyme accordingly.”


    Rémi Buisson, UCI assistant professor of biological chemistry, corresponding author 

    In this study, graduate student Ambrocio Sanchez and postdoctoral fellow Pedro Ortega, both in Buisson’s laboratory at the UCI School of Medicine, developed a new method to characterize the particular kind of DNA modified by APOBEC3A and APOBEC3B. It revealed that the two enzymes do not recognize the same DNA sequences and structures within the genomes of cancer cells. Based on this observation, an innovative approach utilizing these unique target preferences was employed to classify cancer patients who had accumulated mutations caused by each enzyme.

    “The next steps are to investigate whether mutations caused by these enzymes lead to various types of therapy resistance. It’s also critical to identify molecules that inhibit APOBEC3A and APOBEC3B to prevent mutations from forming. Our findings could, in the future, help to assess patient risk before treatment and suppress tumor evolution using the appropriate drug therapy,” Buisson said.

    Other team members included undergraduate and graduate students and postdoctoral fellows from UCI, Harvard Medical School, the University of Southern California, the University of Texas at San Antonio and the University of Minnesota.

    This work was supported by the National Institutes of Health’s Research Supplements to Promote Diversity in Health-Related Research program under award R37-CA252081-S; California Institute for Regenerative Medicine stem cell biology training grant TG2-01152; European Molecular Biology Organization postdoctoral fellowship ALTF 213-2023; Cancer Prevention and Research Institute of Texas research training award RP 170345 and Recruitment of Established Investigators award CPRIT RR220053; the National Cancer Institute under awards R37-VA252081 and P01-CA234228; the National Institute of Allergy and Infectious Diseases under award R01 AI150524; and access to UCI’s Genomics Research and Technology Hub, affiliated with the Chao Family Comprehensive Cancer Center, under grant P30-CA062203.

    Source:

    Journal reference:

    Sanchez, A., et al. (2024). Mesoscale DNA features impact APOBEC3A and APOBEC3B deaminase activity and shape tumor mutational landscapes. Nature Communications. doi.org/10.1038/s41467-024-45909-5.

    [ad_2]

    Source link